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Most probiotic strains commercially available today are lactic acid bacteria, which are included in a 
wide range of product formulations representing a significant sector in the modern functional foods 
market. 
Streptococcus thermophilus is a gram-positive bacterium, widely used in dairy fermentation as starter 
culture for the production of yogurt and cheese, and it has a potential as probiotic. On the other hand, 
when ingested it may not survive to passage through the human gastrointestinal tract. Consequently, 
it is essential to improve cell survivability during gastrointestinal passage, as it is consider a key 
feature of probiotic strains, and the formulation of these probiotics into microcapsules seems to be a 
promising emerging solution in addition to controlled release in their target, the gut, to confer health 
benefit to the host. 
The present study is focused on the evaluation of the best encapsulating matrix/agent to fulfil these 
requirements using an in vitro model of human gastrointestinal tract. The molecules used to form 
sodium alginate based-microcapsules of S. thermophilus TH982, were represented by three molecules 
at 2% (w/v) concentration: a polysaccharide (inulin), a protein (gelatin), and a human milk 
oligosaccharide (2’-fucosyllactose). Also, capsules of sodium alginate alone were used as control.  
The microcapsules were obtained by the extrusion technique, and then the efficiency of the 
encapsulation process was evaluated, revealing a good efficiency for all the materials to entrap 
TH982, since more than 90% of total cells were encapsulated.  
On the other hand, capsules showed a low decrease in the number of entrapped TH982 after 21 days 
in skimmed milk at 4 °C, compared to non-encapsulated cells in the same conditions, indicating that 
it is necessary to entrap a large number of cells to avoid a final count under the recommended least 
viability (107 CFU/g of product at the time of consumption). 
Afterwards, the capsules were exposed to 3 h of in vitro simulated gastric (pH 2.5) and intestinal (pH 
7.5) fluid and the different ability of the encapsulating materials to enhance survival of probiotic 
strain was compared, also with respect to non-encapsulated TH982.  
After stomach and intestine passage, microcapsules were subjected to a simulated intestinal fluid to 
ensure that the different matrices allowed a release of viable probiotic cells in the intestine.  
The oucomes revealed important significant differences among different molecules utilized for the 







La maggior parte dei ceppi probiotici disponibili attualmente in commercio sono i batteri lattici, i 
quali sono inclusi in un’ampia gamma di formulazioni di prodotti che rappresentano un settore 
significativo nel moderno mercato degli alimenti funzionali.  
Streptococcus thermophilus è un batterio gram-positivo, ampiamente utilizzato nella fermentazione 
lattiero-casearia come coltura starter per la produzione di yogurt e formaggio, e possiede un 
potenziale come probiotico. Tuttavia, quando viene ingerito, potrebbe non sopravvivere al passaggio 
attraverso il tratto gastrointestinale umano. Di conseguenza, è essenziale ottimizzare la sopravvivenza 
delle cellule durante il passaggio gastrointestinale, poiché è considerata una caratteristica chiave dei 
ceppi probiotici e l’inclusione di questi probiotici in forma di microcapsule sembra essere una 
soluzione emergente promettente, oltre al controllo del rilascio nel sito bersaglio, l'intestino, in modo 
da conferire benefici per la salute dell'ospite.  
Il presente studio è focalizzato sulla valutazione della matrice/agente incapsulante in grado di 
soddisfare questi requisiti utilizzando un modello in vitro del tratto gastrointestinale umano. Le 
molecole utilizzate per formare le microcapsule, che racchiudono S. thermophilus TH982, a base di 
alginato di sodio, sono rappresentate da tre molecole al 2% (w/v) di concentrazione: un polisaccaride 
(inulina), una proteina (gelatina) e un oligosaccaride del latte umano (2’-fucosillattosio). Inoltre, 
capsule di alginato di sodio da sole sono state utilizzate come controllo.  
Le microcapsule sono state ottenute tramite la tecnica dell'estrusione, e successivamente è stata quindi 
valutata l'efficienza del processo di incapsulamento, rivelando una buona capacità di intrappolare 
TH982 per tutti i materiali (più del 90% delle cellule totali è stato incapsulato).  
D’altra parte, le capsule hanno mostrato una lieve diminuzione del numero di TH982 intrappolato 
dopo 21 giorni nel latte scremato a 4 °C, rispetto alle cellule non incapsulate nelle stesse condizioni, 
indicando che è necessario racchiudere un gran numero di cellule per evitare una popolazione finale 
al di sotto della minima soglia consigliata (107 CFU/g di prodotto al momento del consumo).  
Successivamente, le capsule sono state esposte a 3 ore di fluido gastrico (pH 2,5) e intestinale (pH 
7,5) simulato in vitro e la diversa capacità di migliorare la sopravvivenza del ceppo probiotico è stata 
confrontata tra i materiali usati per le capsule, e in relazione con TH982 non incapsulato.  
Dopo la riproduzione del passaggio nello stomaco e nell'intestino, le microcapsule sono state 
sottoposte a un fluido intestinale simulato per garantire che le diverse matrici consentissero il rilascio 
di cellule probiotiche vitali nell'intestino.  
I risulati hanno rivelato importanti differenze significative tra le diverse molecole utilizzate per 









1 INTRODUCTION  
The concept of “functional foods” was introduced a long time ago with Hippocrates’s motto, “Let 
food be thy medicine.” Recently, evidences started to support the hypothesis that diet may play an 
important role in modulation of important physiological functions in the body (Vasiljevic and Shah, 
2008). 
The term probiotic is a relatively new word derived from the Greek pro bios, which means for life 
(Shortt, 1999). The word “probiotic” was initially used as an antonym of the word “antibiotic”. 
 “The history of probiotics began with the history of man” (Soccol et al., 2010). Cheese and fermented 
milk were well known to the Greeks and Romans, and they suggested their administration for treating 
gastroenteritis, especially in children. Dairy products are also mentioned in the Bible and the sacred 
books of Hinduism (Soccol et al., 2010).  
The fermentation of dairy products was widely recognized and appreciated early, since olden times, 
as observed in some products used by the Pharaonic civilization, such as milk, seeds, fish, and some 
other products (Soccol et al., 2014). It was recognized as one of the oldest methods of food 
preservation. In the late 19th century, scientists realized that a wide range of traditional sour milk 
products had auxiliary therapeutical benefits in addition to prolonged shelf-life and pleasant sensory 
properties (Vasiljevic and Shah, 2008). 
 
1.1 Definition of probiotics 
Probiotics have been defined in several ways, depending on our understanding of the mechanisms of 
action of their effects on humans health and well-being (Salminen et al., 1999).  
At the beginning of the 20th century, the main functions of gut flora were completely unknown. 
Ilya Ilyich Metchnikoff, the Nobel prize winner in Medicine in 1908, was the first who spotted the 
effect of what is called today probiotic. He noticed that Balkans (Bulgarian) peasants had an average 
life-perspective of 87 years, which was not common for the early 1900s. The major difference in 
comparison with the contemporary diet was large ingestion of bacteria (L. delbrueckii subsp. 
bulgaricus and S. thermophilus) present in yogurt. In “The Prolongation of Life”, published in 1907, 
he postulated that “the dependence of the intestinal microbes on the food makes it possible to adopt 
measures to modify the flora in our bodies and replace the harmful microbes by useful microbes.” 
This definition created one of the original hypothesis of the positive role played by certain bacteria: 
their consumption would alter the composition of the intestinal microbiota towards a gut microbiota 
that would increase the host health (Metchnikoff, 1907).  
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From Metchnikoff till today, the probiotic concept has drastically evolved, and different definitions 
of probiotics have been proposed. 
For example, in 1953, the word “probiotika” was used by Werner Kollath, who used it to describe 
the recovery of malnourished patients by different organic and inorganic supplements (Kollath, 
1953).  
A year later, Ferdinand Vergin proposed that probiotics were the opposite of antibiotics, and 
probiotic-rich diet could have restored the microbial imbalance in the body caused by antibiotic 
treatment. This was considered by many as the first reference to probiotics as they are defined 
nowadays (Vergin, 1954).  
Later on, Lilly and Stillwell (1965), after observations of secretions of Colpidium campylum that 
could increase the growth of Tetrahymena pyriformis, defined probiotics as “the secretions of one 
microorganism which stimulate the growth of another microorganism” (Lilly and Stillwell, 1965).  
A powerful evolution of this definition was offered by Parker in 1974, who proposed that probiotics 
are “organisms and substances which contribute to intestinal microbial balance” (Parker, 1974). Many 
authors disputed this definition since even antibiotics might have been included (Vasiljevic and Shah, 
2008). 
In 1989 Fuller attempted to improve Parker’s definition of probiotic with the following distinction: 
“a live microbial feed supplement which beneficially affects the host animal by improving its 
intestinal microbial balance” (Fuller, 1989). This revised definition emphasizes the requirement of 
viable cells as an essential component of an effective probiotic, excludes antibiotics, removing the 
confusion created by the use of the word “substances”, and introduces the concept of a beneficial 
effect on the host, which was, according to his definition, an animal. However, his definition was 
more applicable to animals than to humans. 
This explanation of probiotic was not wide enough to cover the entire indigenous human microflora. 
In 1992, another definition was proposed by Havenaar and Huis In’t Veld: “probiotics are the viable 
mono- or mixed microbial cultures which when applied to animal or man have beneficial effects on 
their host by improving the properties of indigenous microflora” (Havenaar and Huis In’t Veld, 1992). 
In this view, they included the possibility of application to microbial communities at other sites, e.g., 
respiratory tract, urogenital tract, skin, and not only to the intestinal microflora. 
Similarly, in 1996, Salminen broadened the definition of probiotics, defining them as “a live 
microbial culture or cultured dairy product that beneficially influences the host’s health and nutrition” 
(Salminen, 1996). 
A more recent, but not the last definition is “live microorganisms, which when consumed in adequate 
amounts, confer a health effect on the host” (Guarner and Schaafsma, 1998).  
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Although all cited authors agreed that probiotics include live microorganisms, Salminen et al. (1999) 
proposed their view incorporating non-viable bacteria in the following definition: “probiotics are 
microbial cell preparations or components of microbial cells that have a beneficial effect on the health 
and well-being of the host.” This definition implies that probiotics do not necessarily need to be 
viable. Indeed Ouwehand and Salminen (1998) found that non-viable forms of probiotics showed 
health effects. Furthermore, the definition does not restrict the use of probiotics in foods, and not only 
whole microbial cells, but also parts of cells have been observed to improve host health (Salminen et 
al., 1999). 
A number of definitions of the term “probiotic” has been used over the years. Currently, the Food 
and Agriculture Organization (FAO) of the United Nations and World Health Organization (WHO) 
working group best exemplified the breadth and scope of probiotics as they are known today: “live 
microorganisms which, when administered in adequate amounts, confer a health benefit on the host”, 
and this definition was reconfirmed by the FAO in 2006 (FAO/WHO, 2006, 2002). 
In 2014, this definition was revised with a more grammatically correct elucidation by an expert panel 
of the International Scientific Association for Probiotics and Prebiotics (ISAPP) as, “live 
microorganisms that, when administrated in adequate amounts, confer a health benefit on the host” 
(Hill et al., 2014). This definition includes a broad range of microbes and applications, whilst defining 
the essence of probiotics (microbial, live, and beneficial to health). However, the use of the word 
“live” has been controverted since positive effects were also reported for the dead cells (Kareb and 
Aïder, 2019).  
Unfortunately, misuse of the term probiotic has become a significant issue, with many products 
exploiting the term without meeting the requisite criteria. 
 
1.2 Probiotic microorganisms 
Despite these numerous theoretical definitions, however, the practical question arises whether a given 
microorganism can be considered to be a probiotic or not. Havenaar and Huis In’t Veld (1992) 
proposed some strict criteria for designating a strain as a probiotic: total safety for the host, human 
origin, survival to gastric acidity and pancreatic secretions, adhesion to epithelial cells, immune 
modulator activity, production of antimicrobial substances, inhibition of pathogenic bacteria, 
resistance to antibiotics, tolerance to food additives, and stability in the food (Iacono et al., 2011; 
Reid et al., 2003). 
Although numerous criteria have been recognized and suggested, the probiotics in use today have not 
been selected according to all of them.  
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In the last 20 years research in the probiotic area has progressed considerably, and significant 
advances have been made in selecting and characterizing specific probiotic cultures and 
substantiating health claims relating to their consumption (FAO/WHO, 2006). 
In a recent paper, Morelli (2007) pointed out how approaches in probiotic bacteria selection have 
been evolved. Several researchers agreed that probiotic strain should be assessed according to the 
following principle: 
• it must be of human origin; 
• it must survive during gastric transit; 
• it has to tolerate bile salts; 
• it has to adhere to gut epithelial tissue. 
Based on ecological considerations, these criteria have been used to select strains that have been 
successfully tested in vivo and are currently used as probiotics.  
More recently, two additional approaches in probiotic bacteria selection have been suggested by 
FAO/WHO (2006): the in vitro assessment to predict microorganisms functionality in the intestine 
and genomics analysis. The first is related to the activities exerted by probiotics towards what is 
termed gut-associated lymphoid tissue (GALT), while the second is the outcome of the availability 
of the complete genomic sequences of the probiotic strain. There is a large scientific consensus in 
order to assess the properties of probiotic bacterial strains: it is mandatory to perform a preliminary 
in vitro assessment (Morelli, 2007).  
General agreement with regard to potential selection criteria proposed by FAO/WHO (2002) and 
confirmed by many authors (Holzapfel et al., 1998; Vasiljevic and Shah, 2008) are listed in Table 
1.2. 
An important operational definition of the term probiotic requires the organism in question to be 
“consumed in adequate amounts” to confer a benefit. The viability and stability of probiotics have 
been both a marketing and technological challenge for industrial producers. Probiotic foods should 
contain specific probiotic strains and maintain a suitable level of viable cells during the product’s 
shelf-life (Mattila-Sandholm et al., 2002). The standard for any food sold with health claims from the 
addition of probiotics is that it must contain per gram at least 106-107 CFU of viable probiotic bacteria 
(FAO/WHO, 2002).  
The safety of a strain is defined by the absence of association with pathogenicity and the antibiotic 
resistance profile (EFSA, 2005). Probiotics are subject to regulations in the general food law, 
according to which they should be safe for human and animal health. In the USA, microorganisms 
used for consumption purposes should have the GRAS (Generally Recognized As Safe) status, 
regulated by the FDA (Food and Drug Administration). In Europe, EFSA introduced the term QPS 
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(Qualified Presumption of Safety). The QPS concept involves some additional criteria of the safety 
assessment of bacterial supplements, including the history of safe usage and absence of the risk of 
acquired resistance to antibiotics (EFSA, 2005). Also, to define a strain as probiotic, safety aspects 
have to include specifications such as origin (i.e., healthy human gastrointestinal tract) (Mattila-
Sandholm et al., 2002). However, the report of the Expert Consultation on Evaluation of Health and 
Nutritional Properties of Probiotics FAO/WHO (2002) pointed out that, at the moment, it is very 
difficult to identify and confirm the original source of a microorganism. Infants are born without 
bacteria in the intestine, and the origin of the intestinal microflora has not been fully elucidated. It 
was emphasized that the ability to remain viable at a specific target site and to be effective are more 
important than the origin of a specific strain and these properties should be verified for each 
potentially probiotic strain (FAO/WHO, 2006).  
Functional aspects define their survival in the gastrointestinal tract and their immunomodulatory 
effect. The expected characteristics of probiotic microorganisms may include besides the 
physiological, immunological and metabolic activity, several technological properties such as been 
genetically stable strains, have a desired viability during processing and storage, good sensory 
properties and have a large-scale production (Figueroa-González et al., 2011) (Table 1.2).  
It is widely admitted that probiotics must survive through the human gastrointestinal tract (GIT) to 
exert their beneficial health effects. Therefore, they have to resist to GIT stresses, such as low pH, 
bile salts and pancreatic secretions. Besides, the dose required for a probiotic effect is still debated, 
due to fluctuations depending on both the strain and target. Nevertheless, the minimal concentration 
of cells needed to obtain a clinical effect was quoted to be 106 CFU/ml in the small bowel and 108 
CFU/ml in the colon (Uriot et al., 2017). 
Health benefits imparted by probiotic bacteria are strain- and tissue-related and not species- or genus-
specific. Thus, the probiotic effect neither universal to all bacterial species nor all human tissues. 
Moreover, it is important to note that not all the same species’ strains will be effective against defined 
health conditions or to all human tissues (Shah, 2007).  
In addition, probiotic effects seem to be dose-dependent (Minelli and Benini, 2008). 
The use of probiotics has considerably increased and their potential domain of application in human 
clinical care is extremely wide: reduction of blood cholesterol, treatment of inflammatory bowel 
syndrome or gastrointestinal disorders, synthesis of vitamins, protection against antibiotic-associated 
diarrhea, Helicobacter pylori infection, allergic disorders, alleviation of symptoms of lactose 
intolerance, hypercholesterolemia, respiratory infections and even against systemic disease (Aspri et 
al., 2020; Kerry et al., 2018; Stavropoulou and Bezirtzoglou, 2020). The clinical utility of probiotics 
may extend to fields such as allergic disease and cancer. Probiotics have roles in epithelial cell 
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proliferation and differentiation and the development and the homeostasis of the immune system 
(Soccol et al., 2014). 
With regard to the most studied beneficial health effect, probiotics affect intestinal bacteria by 
increasing the numbers of beneficial anaerobic bacteria and decreasing the population of potentially 
pathogenic microorganisms (O’Toole and Cooney, 2008).  
In addition, they might influence the intestinal ecosystem by impacting mucosal immune 
mechanisms, by interacting with commensal or potential pathogenic microbes and by producing 
metabolic end products such as short-chain fatty acids (SCFAs) (De Melo Pereira et al., 2018). These 
mechanisms lead to reduction of potential pathogens, an improved intestinal environment, 
fortification of the intestinal barrier, down-regulation of inflammation, and up-regulation of the 
immune response to antigenic challenges (Markowiak and Ślizewska, 2017).  
These phenomena are thought to mediate the most beneficial effects, including a reduction in the 
incidence and severity of diarrhea, which is one of the most widely recognized uses of probiotics 
(Guarner et al., 2017). 
Many probiotics currently used come from the human intestine in considerable populations, and 
commercially the most important strains are lactic acid bacteria (LAB).  
LAB play an essential role in food fermentations thus, a wide variety of strains are routinely employed 
as starter cultures in the industry of dairy, meat and vegetable products (Chow, 2002). The most 
important contribution of these microorganisms to the product is to preserve the nutritive qualities of 
the raw material through an extended shelf-life and the inhibition of spoilage and pathogenic bacteria. 
This is due to competition for nutrients and the presence of inhibitors produced by the starter, 
including organic acids, hydrogen peroxide, and bacteriocins (O’Sullivan et al., 2002). 
Members of the LAB are usually subdivided into two distinct groups based on their carbohydrate 
metabolism. The homofermentative group, consisting of Lactococcus, Pediococcus, Enterococcus, 
Streptococcus and some lactobacilli, utilizes the Embden-Meyerhof-Parnas (glycolytic) pathway to 
transform a carbon source primarily into lactic acid.  
As opposite, the heterofermentative bacteria produce equimolar amounts of lactate, CO2, ethanol or 
acetate from glucose exploiting phospho-ketolase pathway. Members of this group include 
Leuconostoc, Weissella and some lactobacilli (Klein et al., 1998). 
Lactobacillus and Bifidobacterium genera are most commonly used as probiotics, which are 
considered to be safe based on their historical presence in the human gut and foods.  
Other less common species belonging to the strains of Streptococcus, Saccharomyces, Escherichia 
coli, Lactococcus, and Enterococcus are also used as probiotics due to their safety and great health 
potential (Table 1.1). 
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Table 1.1 - Potentially probiotic cultures used as nutraceuticals and/or in fermented milk. Adapted from 
Champagne (2005); Kumar et al. (2016); Shah (2007). 
Genera Species 
Lactobacillus  acidophilus 
























Lactococcus  lactis subsp. lactis 




Lactobacillus includes different species and the most common are: L. acidophilus, L. rhamnosus, L. 
delbrueckii subsp. bulgaricus, L. reuteri, L. casei, L. johnsonii, L. pantarum. Lactobacilli are 
ubiquitous in nature, found in carbohydrate-rich environments. They are gram-positive, non-spore-
forming microorganisms, catalase-negative, appearing as rods or coccobacilli. Growth occurs at as 
high as 45 °C; however, the optimum growth temperature is between 35-40 °C. The organisms grow 
in slightly acidic media at a pH of 6.4-4.5, but growth ceases when a pH of 4.0-3.6 is reached. The 
majority of the strains are acid-tolerant in the stomach acidity and have a good adherence capacity to 
the intestinal cells.  
Bifidobacterium belong to the phylum of Actinobacteria as they have a characteristic ramified 
morphology. These bacteria are rod-shaped, non-gas producing and anaerobic organisms. They are 
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generally characterized as gram-positive, non-spore forming, non-motile and catalase-negative. The 
most common Bifidobacterium probiotic species are B. animalis, B. bifidum, B. breve, B. infantis, B. 
lactis, B. longum. Optimum growth occurs at a temperature of 37-41 °C and the optimum pH is 6.0-
7.0. Bifidobacterium are normal inhabitants of the human gastrointestinal tract and selected strains 
can survive the stomach and intestinal transit and reach the colon in abundant numbers (Shah, 2007); 
however, the number of bifidobacteria decreases with increasing the age of the host. 
 
Table 1.2 - Key and desirable criteria for the selection of probiotics strains. Adapted from Markowiak and 
Ślizewska (2017); Vasiljevic and Shah (2008); Morelli (2007). 
Criterion Required property 
Safety 
Human or animal origin  
No adverse effects 
History of safe use 
Absence of data regarding an association with infective disease 
Absence of genes responsible for antibiotic resistance localized in non-stable elements 
Functionality 
Tolerance to gastric acid and juices  
Bile tolerance  
Adhesion to mucosal surface 
Resistance to bacteriocins and acids produced by the endogenic intestinal microbiota  
Validated and documented health effects 
Antagonistic activity towards pathogens (e.g., H. pylori, Salmonella spp., Listeria 
monocytogenes, Clostridium difficile) 
Competitiveness with respect to microbial species inhabiting the intestinal ecosystem 
Technological 
Guarantee of desired sensory properties of finished products 
Genetic stability 
Resistance to bacteriophages 
Large-scale production 
Desired viability during processing and storage 
 
 
Probiotic bacteria are included in a wide range of products, including yoghurts, drinks, capsules, and 
dietary supplements, and they represent a significant element in the modern functional foods market.  
The use of diet to fortify certain gut flora components is a popular current aspect of functional food 
sciences. In this context prebiotics, synbiotics and postbiotics all have a significant role. 
 
1.2.1 Prebiotics 
In contrast to probiotics, which are viable organisms, prebiotics describe non-viable food components 
(Geurts et al., 2014).  
In 1995, prebiotics were described by Gibson and Roberfroid as “non-digestible food ingredient that 
beneficially affects the host by selectively stimulating the growth and/or activity of one or a limited 
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number of bacterial species already established in the colon, that can improve host health” (Gibson 
and Roberfroid, 1995). In 2004, the definition was updated, and prebiotics were defined as a 
“selectively fermented ingredient that allows specific changes, both in the composition and/or activity 
in the gastrointestinal microflora that confers benefits upon host wellbeing and health” (Gibson et al., 
2004). Finally, in 2007, FAO/WHO experts described prebiotics as a “nonviable food component that 
confers a health benefit on the host associated with modulation of the microbiota” (Chen et al., 2005; 
Pineiro et al., 2008).  
In 1999, Fooks et al. selected some principles which allow the classification of food ingredients as a 
prebiotic, confirmed in 2009 by Wang:  
• they must be not digested (or just partially digested), hydrolyzed or adsorbed in the upper part 
of the gastrointestinal tract;   
• as a consequence, they reach the colon, where they are selectively fermented by potentially 
beneficial bacteria; 
• the fermentation leads to increased production in the relative abundance of different SCFAs, 
a moderate reduction of colonic pH, reduction of nitrous end products and an improvement 
of the immunological system (Crittenden and Payne, 2008), which is beneficial for the host; 
• selective stimulation of growth and/or activity of the colonic microbiota potentially associated 
with health protection and wellbeing; 
• preferably, prebiotics must be able to endure food processing conditions and remained 
unchanged, non-degraded, or chemically unaltered and available for bacterial metabolism in 
the intestine. 
Any foodstuff that is not digested by host enzymes and reaches the colon in a practically unaltered 
form (e.g., non-digestible carbohydrates, some peptides and proteins, as well as specific lipids) where 
they are fermented by saccharolytic bacteria (e.g., Bifidobacterium genus), is a candidate prebiotic.  
There are many reports on the beneficial effects of prebiotics on human health. Different studies have 
suggested that prebiotics affect intestinal bacteria by increasing beneficial anaerobic population, 
corresponding to stimulation of bifidobacteria and lactobacilli growth, thus conferring important 
changes in gut microbiota composition and decreasing potentially pathogenic microorganisms 
(Guarner et al., 2017; Hill et al., 2014). 
In addition, further health benefits promoted by prebiotics are: reducing the prevalence and duration 
of diarrhea, providing relief from inflammation and other symptoms associated with intestinal bowel 
disorders, and exerting protective effects to prevent colon cancer. Prebiotics are also implicated in 
enhancing the bioavailability and uptake of minerals, lowering some risk factors for cardiovascular 
disease, and promoting satiety and weight loss (Kerry et al., 2018). 
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However, it should be considered that an overdose of prebiotics may lead to flatulence and diarrhea. 
This effect is absent in the case of excessive consumption of probiotics, in fact they can be consumed 
on a long-term basis and for prophylactic purposes (Markowiak and Ślizewska, 2018). 
There are evidence that the consumption of diets rich in prebiotics is associated with reductions in 
food intake, body fat content, and body weight gain, especially in overweight and obese individuals 
(Roberfroid et al., 2010). Dewulf et al. (2013) observe that consumption of prebiotics, compared to a 
placebo, in obese women, showed complex modulation of the beneficial gut microbial cells after 
prebiotic treatment: an increase in bifidobacteria is the most common signature of prebiotic treatment 
with inulin-type fructans. 
Furthermore, Bielecka et al. (2002) have shown the relevance of combining prebiotics and probiotics, 
demonstrating greater effectiveness than probiotics alone.  
Prebiotics are naturally occurring in human and animal diets, but they may also be added to food. 
They can be obtained naturally from sources like vegetables, fruits, and grains consumed in our daily 
life. Those substances may serve as a medium for probiotics: prebiotics stimulate their growth and 
contain no microorganisms (Kerry et al., 2018). 
Natural sources of potential prebiotics are: tomatoes, artichokes, bananas, starchy fruits, asparagus, 
berries, garlic, onions, chicory, green vegetables, legumes, beans, as well as oats, linseed, barley, and 
wheat (Crittenden and Payne, 2008; Markowiak and Ślizewska, 2017). Habitually they are used as 
food ingredients in, for example, biscuits, cereals, chocolate, spreads, and dairy products (Markowiak 
and Ślizewska, 2018). 
In particular, many food oligosaccharides (between ~2 and 20 saccharide units) and polysaccharides 
(including dietary fiber) have been claimed to have prebiotic activity, but not all dietary carbohydrates 
are prebiotics (Kolida and Gibson, 2007). There is accumulating evidence, by in vitro and in vivo 
studies, that the most commonly known prebiotics are: inulin-type fructans (ITF), 
galactooligosaccharides (GOS), fructooligosaccharides (FOS), isomaltooligosaccharides (IMO), 
xylooligosaccharides (XOS), transgalactooligosaccharides (TOS), soybean oligosaccharides 
(SBOS), and lactulose (Guarner et al., 2017). 
Also, polysaccharides such as cellulose, hemicellulose, or pectin may potentially be prebiotics 
(Patterson and Burkholder, 2003). Similarly, the use of lactitol, stachyose, raffinose, and saccharose 
as prebiotics requires further studies (Vallianou et al., 2020) .  
Carbohydrates, such as dietary fiber, are potential prebiotics. Prebiotic and dietary fiber are terms 
used alternatively for food components that are not digested in the gastrointestinal tract; however, 
there is a significant difference between those two terms: prebiotics are fermented by strictly defined 
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groups of bacteria, while dietary fibers are used by the majority of colonic microorganisms 
(Ouwehand et al., 2005). 
Prebiotics have enormous potential for modifying the gut microbiota, but these modulations occur at 
the level of individual strains and species, and thus they cannot be proved theoretically.  
 
1.2.1.1 Inulin-Type Fructans 
Inulin-type fructans (ITF) are the most widespread and researched current prebiotics. ITF are present 
in significant amounts in several fruits and vegetables (Table 1.3). However, these natural sources 
contain only trace levels of prebiotics, so functional food developments have considered the approach 
of removing the active ingredients from such sources and adding them to more frequently consumed 
products to reach an inulin dose of 5-8 g/d that is sufficient to elicit a positive effect on the gut 
microbiota (Kolida and Gibson, 2007).  
Industrial production of inulin almost exclusively uses chicory roots as raw material that belongs to 
the Compositae family. The manufacturing process for inulin is similar to that of sucrose extracted 
from sugar beets (Figure 1.1): the chicory roots are harvested, sliced, washed, and inulin is extracted 
from the root by using a hot water diffusion process, then purified and dried (Armisen and Galatas, 
2009). Native chicory inulin is obtained as white powder with fine particles with greater clarity and 
it is a non-fractionated inulin that always contains 6-10% sugars represented as glucose, fructose, 
sucrose, and small oligosaccharides (Roberfroid, 2005).  
For the extraction of oligofructose, the process is the same, but one more step is added: partial 
enzymatic hydrolysis after extraction. Inulin is broken down using an endo-inulinase (EC 3.2.1.7) 
into chain lengths ranging from 2 to 10, with an average DP (i.e., degree of polymerization) of 4 
(Niness, 1999). Oligofructose can otherwise be obtained by enzymatic synthesis (transfructosylation) 
using the fungal enzyme β-fructosidase (EC 3.2.1.7) from Aspergillus niger.  
By applying specific separation technologies, it is also possible to eliminate the oligomers with DP < 
10 to produce a high-molecular-weight (long-chain) inulin-type fructan or inulin HP (Roberfroid, 
2007). 
ITF and oligofructose are part of our daily diet, and thus they are classified as food ingredient, and 
they have no E-number (not as additives) in all EU countries. In the USA, a panel of experts has 




ITF is the generic term applied to a linear polydisperse mixture of β-2-1 linked D-fructose molecules, 
otherwise called β-(2,1) fructans. The chain length is a function of the source and moment of 
harvesting (Armisen and Galatas, 2009) and the DP, generally between 10 and 65. Inulin is built up 
of 2 ± 60 fructose units with one terminal D-glucose molecule (Figure 1.2) (De Vos et al., 2010). 
The term oligofructose or fructo-oligoaccharides, a subgroup of inulin, is used for β-(2,1) fructans 
with a DP < 10. Indeed, oligofructose and (short-chain) fructo-oligosaccharides are considered to be 
synonyms to name the mixture of small inulin oligomers (Roberfroid, 2005). 
The β-configuration of the anomeric C2 in the fructose monomers confers to ITF the capacity to resist 
hydrolysis by human small intestinal digestive enzymes, which are specific for α-glycosidic bonds. 
They have thus been classified as “non-digestible” oligosaccharides (Roberfroid, 2005). After 
reaching the colon, they are broken down and utilize through fermentation by bifidobacteria, as they 
possess the β-fructofuranosidase enzyme, providing a competitive advantage in a mixed culture 
environment such as the human gut (Kolida and Gibson, 2007). This attitude explains why ITF are 
classified as dietary fibers.  
The prebiotic or bifidogenic effect of inulin and oligofructose has been well established. As described 
above, ITF are fermented in the large intestine, leading to a stimulation of growth and/or activity of 
several potentially beneficial intestinal bacteria, specifically bifidobacteria and lactobacilli. This 
Figure 1.1 - Industrial production process of chicory inulin and oligofructose (Franck, 2002). 
DP = degree of polymerization 
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effect has been observed in children (Kim et al., 2007) and adults (Kolida et al., 2007), with a decrease 
in the number of potentially harmful species (Clostridium spp. and Bacteroides spp.). 
According to Williams et al. (1994), the administration of the lower dose of 4 g/d of oligosaccharides 
showed a significant increase in beneficial bacterial groups (bifidobacterial and lactobacilli) count, 
and Streptococcus spp. responded positively to the mixture of oligosaccharides. The cells have been 
enumerated after recovering from fecal matter.  
 
 
The fermentation process products are SCFAs: acetic, propionic, and butyric acid. They can be 
absorbed and metabolized by the host, and only a third of the caloric content compared with digestible 
carbohydrates is liberated by this process. This explains why ITF and oligofructose are low caloric 
food ingredients with a caloric value of about 1.5 kcal/g or 6.3 kJ/g, and thus they are suitable 
ingredient for diabetics’ food (Armisen and Galatas, 2009). 
When inulin is fermented by bifidobacteria and SCFAs are produced, it results in a local pH decrease 
of the large intestine and subsequently an increased in various salts solubility. In fact, calcium 
available in diet as a mineral or in association with other components should be in ionized form prior 
to its absorption (Scholz-Ahrens and Schrezenmeir, 2002). Subsequently, the low pH increases the 
bioavailability of calcium, as well as magnesium and iron (Shoaib et al., 2016). 
Additionally, inulin has a notable capacity to replace fat, improving satiety feeling and energy intake. 
When it is mixed with water or another aqueous liquid, it forms a particle gel network resulting in a 
creamy white structure, which can easily be incorporated into foods to replace fat by up to 100% 
(Franck, 2002).  
Figure 1.2 - Structure of inulin (De Vos et al., 2010). 
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Oligofructose is composed of shorter-chain molecules and possesses functional qualities similar to 
sugar or glucose syrup. It is useful to partially replace the sucrose molecule’s flavor as it provides up 
to 35% of the sweetness of table sugar, and in addition, it is more soluble than sucrose (Villegas et 
al., 2010). 
The ability to be not digested by small intestinal enzymes qualifies inulin as a matrix molecule for 
microcapsules because it can reach the colon and survive the upper part of the gastrointestinal tract 
(De Vos et al., 2010). Moreover, it is cheap, has many health benefits, and can be applied in 
combination with almost all encapsulation techniques. 
 
1.2.1.2 Human Milk Oligosaccharides 
In milk from most species, the prevalent soluble glycan is lactose; in particular, in human milk, lactose 
is present at concentrations that average 70 g/l (Castanys-Muñoz et al., 2013). It is a digestible 
disaccharide which provides readily available energy for newborn mammals: in the human small 
intestine, it is hydrolyzed into its monosaccharide building blocks glucose (Glc) and galactose (Gal), 
which are then absorbed. In addition, human milk contains a high concentration of diverse soluble 
oligosaccharides, carbohydrate polymers formed from a small number of monosaccharides (German 
et al., 2008). The oligosaccharides represent the third-largest substantial component: they can be 
found in 10 g/l (1%) of mature human milk (Newburg, 2005), and the highest concentration is 
detected in colostrum (20 g/l) (Coppa et al., 1993). These free soluble milk glycans are known as 
human milk oligosaccharides (HMOs). 
HMOs are synthesized in the mammary gland by specific enzymes, the glycosyltransferases, by 
adding sequentially one or more monosaccharide units (galactose, fucose, N-acetyl-glucosamine, 
sialic acid) to the primary acceptor molecule of lactose, thus forming compounds with both linear and 
branched structures (Coppa et al., 2004). Therefore, lactose is found at the reducing end of all milk 
oligosaccharides (Castanys-Muñoz et al., 2013).  
A peculiar characteristic of such substances is that these monosaccharides are linked by specific 
bonds resistant to the enzymes present in the newborn intestinal wall (lactase, saccharase-isomaltase, 
maltase-glucoamylase, amylase). As a consequence, most oligosaccharides ingested with mother’s 
milk pass through the small intestine undigested and reach the colon (Coppa et al., 2004). In this 
regard, the nutritional function most attributed to milk oligosaccharides is to act as soluble prebiotic 
fiber. There is increasing evidence that HMOs have other functions as well as interaction with 
immune and epithelial cell receptors, protection of breastfed infants against infections, and 
inflammation. 
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The most abundant HMO in human breast milk, which is also available via large-scale commercial 
production, is the trisaccharide 2’-fucosyllactose (Figure 1.3).  
 
2’-fucosyllactose 
One fucosylated substrate of commercial interest for its prebiotic attribute is 2’-fucosyllactose (2’-
FL), which has been detected in human milk. 2’-FL can be found in levels of about 2-3 g/l, which 
counts for approximately 20-25% of total HMOs (Chaturvedi et al., 2001).  
An attractive characteristic of 2’-FL is its simplicity, which facilitates its de novo synthesis using 
microbial, enzymatic, or chemical methods (Coulet et al., 2014). 
 
 
This HMO is not present in milk produced by all women, and its concentration varies significantly 
during lactation and among mothers. This is due to the enzymes necessary for the synthesis of these 
structures, which are gene products that are not uniformly distributed amongst humans, depending 
on the genotype of the mother (Thurl et al., 1997). In particular, the synthesis of 2’-FL requires a 
fucosylation reaction catalyzed by the human α(1→2) fucosyltransferase (E.C.2.4.1.69), or FucT2 
(Albermann et al., 2001). An isomer of the 2’-FL present in human milk is 3-fucosyllactose (3-FL) 
with concentrations of 0.3 to 0.58 g/l in breast milk (Castanys-Muñoz et al., 2013; Christensen et al., 
2020). 
As above-mentioned, there are variations in the productions of 2’-FL between lactating women due 
to differential expression of FucT2, which is associated with the same genes that determine Lewis-
blood type and Secretor status (Viverge et al., 1990). Other aspects may influence the secretion of 2’-
FL, such as general biological variability, ethnicity, and period of lactation (Thurl et al., 2017). 
During the last decade, an increasing amount of evidence supporting the potential beneficial effects 
of 2’-FL as a bioactive molecule has been reported. These properties can be divided into two groups 
Figure 1.3 - Structure of 2'-fucosyllactose and possible abbreviation name (Christensen et al., 2020). 
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according to their mechanism of action: a direct effect on the infant by interacting with cells and 
tissues, and an indirect effect by interacting with beneficial microbiota and pathogens. 
The most common causes of infant mortality are infections caused by bacteria and viruses. These 
pathogens need to attach to specific target cell surface glycans as the first step in pathogenesis, using 
carbohydrate-binding proteins called adhesins or microbial lectins (Kunz et al., 2000). Fucosylated 
glycans, such as 2’-FL, may prevent bacterial infections promoting intestinal anti-adhesive function. 
This is due to the fact that specific HMOs and cell surface glycoproteins and glycolipids (i.e., human 
cell surface glycans) are synthesized by the same types of glycosyltransferases (Figure 1.4). Hence 
they would be expected to have structural moieties in common (Chaturvedi et al., 2001; Newburg et 
al., 2005). In conclusion, 2’-FL from human milk may act as a decoy, inhibiting pathogens’ ability to 
bind to receptors in the gut and thereby protect the breastfed infant from diarrhea (Kunz et al., 2000).  
 
 
The most common cause of bacterial diarrhea in human is Campylobacter jejuni (Ruiz-Palacios et 
al., 2003). In particular, C. jejuni binds specifically to the H-2 epitope (a fucosylated glycan) on 
human intestinal epithelium’s cell surface. Ruiz-Palacios et al. (2003) found that such binding was 
inhibited in vitro by the presence of the milk oligosaccharide 2’-FL exerting competitive binding.  
Human milk has also been tested for the ability to inhibit stable toxin (ST) of E. coli that causes 
diarrhea. ST are known to use 2-linked fucosylated glycoconjugates as receptors, as well as C. jejuni 
(Newburg et al., 2004). According to Coppa et al. (2006), ST from enterotoxigenic E. coli is inhibited 
by 2-linked fucosylated oligosaccharides such as 2’-FL. Furthermore, they demonstrated for the first 
time that human milk oligosaccharides inhibit the adhesion to epithelial cells of aggressive bacteria 
as Vibrio cholerae and Salmonella fyris.  
In conclusion, they stated that “oligosaccharides are one of the important defensive factors contained 
in human milk against acute diarrheal infections of breastfed infants” (Coppa et al., 2006). 
The prerequisite for prebiotic activity, attributed to 2’-FL, is to resist enzymatic hydrolysis in the 
gastrointestinal tract. Brand-Miller et al. (1998) provided the first hypothesis that HMOs escape small 
Figure 1.4 - Biosynthesis of fucosylated oligosaccharide 2’-FL. It requires the presence of the sugar 
nucleotide guanosine diphospho-fucose (GDP-Fuc or GDP-     ), which acts as a donor of fucose residues 
(Castanys-Muñoz et al., 2013). 
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intestinal digestion and reach the colon to be fermented by microbiota. Twenty-four healthy breastfed 
infants have been studied and the breath hydrogen responses to a loading dose of the non-digestible 
sugar (lactulose) with that after an equivalent load of HMO have been compared. Lactulose is 
nondigested in the human small intestine but is fermented by bacteria with the production of hydrogen 
that is easily detected in exhaled air (Engfer et al., 2000). They found that the hydrogen-exhalation 
profile in infants was not significantly different from that after administration of the equivalent 
amount of lactulose over 4 hours. In conclusion, this is an indirect proof suggesting that HMOs, of 
which 2’-FL is the more abundant, resist digestion in the small intestine, and subsequently, they are 
fermented by bacteria when they reach the colon (Brand-Miller et al., 1998). 
This outcome has been further investigated by Engfer et al. (2000), which showed that essentially no 
hydrolysis occurs in the small intestine, suggesting that the oligosaccharides may reach the colon in 
an intact form where they serve as substrates for bacterial metabolism, fulfilling the prerequisites 
required to function as prebiotics. This was supported by the detection with MALDI-MS of the HMOs 
fraction recovered after digestion, and no hydrolysis products have been identified. Therefore, HMOs 
might be considered the soluble fiber portion of human breast-milk and thus may stimulate the growth 
of microorganisms such as bifidobacteria or lactobacilli and produce SCFAs, which facilitate salts 
and water absorption (Engfer et al., 2000; Gnoth et al., 2000). 
HMOs have been detected in the urine of breastfed, but not formula-fed infants, suggesting that they 
may also act at a systemic level. Since ~1% of the HMOs are absorbed and reach the systemic 
circulation (Bode, 2009), it is thus probable that they would exert their protective effect in the urinary 
tract (Martín-Sosa et al., 2002) or modulation of immune responses (Bode, 2012). 
 
1.2.2 Synbiotics 
High potential is attributed to the simultaneous use of probiotics and prebiotics (Table 1.3).  In 1995, 
Gibson and Roberfroid, introduced the term “synbiotic” to describe a “combination of synergistically 
acting probiotics and prebiotics” (Gibson and Roberfroid, 1995). As the word “synbiotic” implies 
synergy, the term should be used for those products in which a prebiotic component selectively 
promotes a probiotic microorganism (Cencic and Chingwaru, 2010). An example is fermented dairy 
products, like yogurt and kefir, which are considered synbiotic because they contain live bacteria 
(probiotics) and the food source (prebiotics) needed for them to thrive.  
The principal purpose of this combination is the improvement of the survival of probiotics in the 
gastrointestinal tract (Schrezenmeir and de Vrese, 2001). Without its food source, a probiotic would 
have hurdles surviving in the digestive system because it cannot tolerate low pH and high temperature 
(Crittenden and Payne, 2008). 
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A synbiotic product exerts both a prebiotic and probiotic effect, maintaining the balance of the gut 
flora in healthy individuals and restoring the equilibrium in individuals whose gastrointestinal 
microbiota has been altered due to illness and/or disease, age, or diet. 
Furthermore, in vitro studies have shown that synbiotics are more efficient at modulating gut 
microflora compared to the activity of the probiotics or prebiotics alone (Bengmark, 2005). 
 
1.2.3 Postbiotics 
One additional significant term is “postbiotic”. Currently, the term “postbiotic”, also known as 
metabiotics, denote “soluble bacterial components with biological activities which are believed to be 
safer than the use of whole bacteria” (Stavropoulou and Bezirtzoglou, 2020; Tsilingiri et al., 2012). 
Recent studies, performed by Patel and Denning (2013), showed that bacterial products, recognized 
as postbiotics, may have similar effects on signaling pathways and barrier function in the absence of 
viable organisms. From this view, the following definition was stated: “non-viable bacterial products 
or metabolic byproducts from probiotic microorganisms that have biologic activity in the host” (Patel 
and Denning, 2013).  
Most common types of postbiotics are metabolic byproducts, such as bacteriocins, organic acids, 
ethanol, diacetyl, acetaldehydes, hydrogen peroxide, peptides, enzymes, teichoic acids, vitamins, and 
SCFAs. However, it is also found that certain heat-killed probiotics can also retain important bacterial 
structures that may exert biological activity in the host (Vallianou et al., 2020) (Table 1.3). SCFAs 
are metabolites produced by gut microbiota via the fermentation of non-digestible carbohydrates, thus 
monocarboxylic acids, known for their abundance in plasma and intestines. The most important 
SCFAs are acetate, propionate, and butyrate (De Vadder et al., 2014). Furthermore, researches 
showed that these metabolic byproducts have a broad inhibitory property toward pathogenic microbes 
and, therefore, they can be used as an alternative to antibiotics (Kerry et al., 2018). 
In 2009, Mileti et al. (2009) proposed a study to investigate the possible activity of postbiotics, and 
they detected that a potent postbiotic could protect against the inflammatory properties of invasive 
Salmonella spp. on healthy tissue and also downregulate ongoing inflammatory processes in IBD 
(inflammatory bowel disease) tissue. “Postbiotics may be a safe alternative to probiotics during the 





Table 1.3 - Postbiotics and prebiotics and their natural sources (Kerry et al., 2018). 
Bioactive compounds Natural sources 
Postbiotics   
Bacteriocins Lactobacillus plantarum I-UL4  
Heat-killed LGG  Lactobacillus rhamnosus 
Soluble mediator Lactobacillus paracasei 
Butyrate  Faecalibacterium prausnitzii  
Polyphosphate Lactobacillus brevis 
Exopolysaccharides  Lactobacillus pentosus  
Short-chain fatty acids Lactobacillus gasser 
Prebiotics   
Fructo-oligosaccharides Onion, Leek, Asparagus, Chicory, Jerusalem artichoke, Garlic, Wheat, Oat 
Inulin 
Agave, Banana/Plantain, Burdock Camas, Chicory, Coneflower, Costus, 
Dandelion, Elecampane, Garlic, Globe artichoke, Jerusalem artichoke, Jicama, 
Leopard's bane, Mugwort root, Onion, Wild yam 
Isomalto-oligosaccharides  Miso, Soy, Sauce, Sake, Honey 
Lactulose Skim milk 
Lactosucrose  Milk sugar 
Galacto-oligosaccharides Lentil, Human milk, Chickpea/hummus, Green pea, Lima bean, Kidney 
Soybean oligosaccharides  Soybean 
Xylo-oligosaccharides  Bamboo shoot, Fruits, Vegetables, Milk, Honey 
Fructo-oligosaccharides  Onion, Chicory, Garlic, Asparagus, Banana, Artichoke 
Arabinoxylan Bran of grasses 
Arabinoxylan oligosaccharides  Cereals 
Resistant starch-1,2,3,4 Beans/legumes, Starchy fruits and vegetables (e.g., bananas), Whole grains 
 
1.3 Streptococcus thermophilus 
Streptococcus thermophilus is frequently isolated from dairy environments, but recently, Michaylova 
et al. (2007) reported for the first time isolation and characterization of L. delbrueckii subsp. 
bulgaricus and S. thermophilus strains from plant samples (Cornus mas) in Bulgaria.  
S. thermophilus is a gram-positive bacterium widely used in dairy fermentation for the production of 
yogurt and cheese. It is recognized as anaerobic, aerotolerant, catalase-negative, oxidase-negative, 
showing ovoid cells occurring in pairs or short chains. It is a thermophilic bacterium with an optimal 
growth temperature of 42 °C. 
S. thermophilus is part of the genus Streptococcus (currently known to have more than 70 species), 
which includes several pathogens (e.g., S. pneumoniae, S. pyogenes, S. agalactiae); however, it has 
a GRAS status in USA and a QPS status in the European Union, due to a long history of safe use in 
food production.  
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Since S. thermophilus diverged from its pathogenic relatives, several of the acquired genes appear to 
originate from other dairy species, such as Lactococcus lactis and L. delbrueckii subsp. bulgaricus, 
contributing to its adaptation to milk, a well-defined, narrow ecological niche. Moreover it has lost 
most of the genes responsible for virulence and pathogenic traits (Hols et al., 2005). In particular, 
genes acquired through horizontal transfer, which encode various functions, such as bacteriocin 
biosynthesis, lactose and urea utilization, cell-envelope protease and proteins involved in peptide 
uptake, and exopolysaccharide biosynthesis have been revealed after genomic analysis (Hols et al., 
2005). The milk-driven speciation of S. thermophilus is also supported by the fact that this species is 
rarely isolated outside the dairy environment (Martinović et al., 2020). 
The genome of S. thermophilus is the smallest genomes compared to other LAB and other 
Streptococcus strains (Shi et al., 2015). S. thermophilus is related to L. lactis but is phylogenetically 
closer to streptococcal species of the viridans group, which is divided into five categories: mutans, 
anginosus, sanguinus, mitis, and salivarius. The last one includes S. salivarius, S. vestibularis and S. 
thermophilus. S. salivarius and S. vestibularis are commensal bacteria of the oral and gastrointestinal 
cavities and genital tract (Kawamura et al., 1995). 
The taxonomic status of S. thermophilus has been controversial: it was classified as a S. salivarius 
subspecies (S. salivarius subsp. thermophilus) until Schleifer et al. (1991) through DNA-DNA 
hybridization studies under stringent conditions and physiological data provided sufficient evidence 
for conferring species rank on S. salivarius subsp. thermophilus. 
 
1.3.1 Technological and functional attributes of S. thermophilus  
S. thermophilus is the second most important species of industrial LAB after L. lactis, and one of the 
basic starter bacteria of yogurt. S. thermophilus is the only Streptococcus species used in the food 
industry.  
Beyond the common practice in combination with L. delbrueckii subsp. bulgaricus in yoghurt, S. 
thermophilus is used to produce several varieties of so-called hard “cooked” cheeses (e.g., Swiss 
cheese, Brick cheese, Parmesan, Provolone, Mozzarella, and Asiago) at a relatively high process 
temperature (45 °C). In the cheese industry, S. thermophilus is mainly used in the refining of hard 
cheeses through the production of aromatic compounds from amino acids due to its glutamate 
dehydrogenase activity. 
One of the main functions of S. thermophilus in yoghurt production is to provide rapid acidification 
through the conversion of lactose into lactic acid. This aspect is linked to food safety, since most 
pathogenic bacteria grow very slowly or not at acidic pH. In addition to lactic acid, it also produces 
secondary fermentation products such as formate, acetoin, diacetyl, acetaldehyde, and acetate, which 
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contribute to the typical aromatic flavor of fermented products, while the creation of the viscous 
texture is provided by the production of exopolysaccharides. 
Furthermore, S. thermophilus has several technological properties, such as sugar metabolism, 
galactose utilization, proteolytic activity, and urease activity. These diverse technological abilities 
represent the phenotypic diversity existing within the species (Iyer et al., 2010b). 
Therefore, in contrast with other LAB, the probiotic status of S. thermophilus remains a point of 
debate.  
 
1.3.2 Probiotic attributes of S. thermophilus 
S. thermophilus is well known for several functional and technological attributes such as the 
production of extracellular polysaccharides, bacteriocins, and biosynthesis of folate. Besides, it also 
has potential as a probiotic, as demonstrated by various health effects. 
S. thermophilus is of nonhuman origin, and although it is known to be sensitive to acidic gastric 
conditions, it has been shown to survive gastrointestinal transit and moderately adhere to intestinal 
epithelial cells (Iyer et al., 2010b). Therefore, S. thermophilus could be considered as a transient 
probiotic (Collins et al., 1998; Iyer et al., 2010b).  
A large number of in vivo studies in humans or animals have also shown beneficial health effects for 
S. thermophilus, such as improving intestinal microflora and lactose digestion in lactose-intolerant 
individuals (Shah, 2007), stimulating the gut immune system (Delorme, 2008), production of high 
quantity of folate extracellularly (Tarrah et al., 2018), and prevention of infectious diarrhea (Canani 
et al., 2007). 
Nevertheless, the available data should be interpreted with caution as in most of these studies, S. 
thermophilus was administrated with another LAB strain or within yogurt (Uriot et al., 2017). 
Also, it is necessary to take into consideration that the survival and beneficial effects of S. 
thermophilus are widely strain-dependent, as other probiotic microrganisms; hence it is expected that 
only certain strains could obtain the probiotic status after clinical studies.  
 
1.3.2.1 Alleviation of lactose intolerance 
Among the above-mentioned LAB, S. thermophilus and L. delbrueckii subsp. bulgaricus, which are 
traditionally used in yoghurt production, have not been considered probiotics during a long time by 
most scientists because some studies reported that they do not survive in the gastrointestinal tract and 
are not natural inhabitants of the intestine (Senok et al., 2005).  
However, in 2010, the European Food Safety Authority (EFSA) has granted a health claim, 
formulating that “a cause-and-effect relationship has been established between the consumption of 
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live yoghurt cultures in yoghurt and improved digestion of lactose in yoghurt in individuals with 
lactose maldigestion” (EFSA, 2010). Individuals with lactose intolerance suffer from excessive 
flatulence, abdominal pains, and diarrhea due to a deficiency of the enzyme β-galactosidase in the 
small intestine. When the β-galactosidase is present, lactose is hydrolyzed into its constituent 
monosaccharides, glucose and galactose, which are transported across the small intestine epithelium. 
These two cultures contain substantial quantities of β-D-galactosidase (Shah, 2007), and thus yoghurt 
is well tolerated by individuals with lactose maldigestion. 
To bear the claim, yogurt must contain at least 108 CFU live microorganisms of L. delbrueckii subsp. 
bulgaricus and S. thermophilus per gram of fermented product (EFSA, 2010). The claim has been 
attributed to yogurt containing both bacteria, but not to S. thermophilus alone. 
Then, even if the beneficial effect of yogurt on alleviation of lactose intolerance is well established 
by clinical studies, yet no solid evidence in humans has been presented to state that this effect can be 
specifically attributed to S. thermophilus (Uriot et al., 2017). Even if yoghurt properties are approved 
by EFSA, the probiotic status of S. thermophilus is still questioned.  
 
1.3.2.2 Proteolytic system 
LAB are nutritionally fastidious, needing an exogenous supply of amino acids to initiate growth (Iyer 
et al., 2010b). 
The proteolytic system of S. thermophilus is similar to that found in other LAB. It includes more than 
20 proteolytic enzymes, divided into (Hols et al., 2005):  
• an extracellular cell-anchored protease capable of casein hydrolysis; 
• a set of amino acid and peptide transport systems required for import of amino acids; 
• a set of intracellular peptidases involved in the hydrolysis of casein-derived peptides essential 
for various house-keeping processes. 
Most of S. thermophilus strains appear to be auxotrophic. They require an exogenous supply of amino 
acids for growth (at least four amino acids: Glu, Cys, His, and Met), while other LAB are known to 
be less demanding. 
Since milk contains low quantities of free amino acids and short peptides, optimal growth of S. 
thermophilus in milk requires hydrolysis of caseins, internalization and hydrolysis of the resulting 
peptides, or de novo amino acid biosynthesis (Hols et al., 2005). Bacteria used for yoghurt production 
release higher amounts of free amino acids and have greater aminopeptidase and dipeptidyl-peptidase 
activity than the others probiotic bacteria. As a result, yogurt bacteria grow faster in milk, whereas 
other bacteria grow slowly due to low proteolytic activity.  
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S. thermophilus has also been studied for its ability to hydrolyze the major whey proteins, β-
lactoglobulin (BLG) and α-lactalbumin (ALA), increasing the digestibility (El-Zahar et al., 2004). 
The catabolism of amino acids plays an important role in providing precursors for the biosynthesis 
of amino acids, nucleotides, vitamins, and the production of a large number of key aroma compounds 
of yoghurt.  
Helinck et al. (2004) tested three LAB species, and revealed that only S. thermophilus exhibit GDH 
(glutamate dehydrogenase) activity that produced α-KG (α-ketoglutarate), an aroma compound from 
glutamate transamination; however, the intensity of activity was strain-dependent (Helinck et al., 
2004). 
The characteristic flavour component in yoghurt, acetaldehyde, is also essentially a product of amino 
acid catabolism. The relatively high concentration of acetaldehyde (in the range of 5 to 21 mg/l) in 
yogurt could be due to a low utilization rate of this metabolite since S. thermophilus lacks alcohol 
dehydrogenase, the main enzyme for acetaldehyde conversion into ethanol.  
In addition, Chaves et al. (2002) suggested that, in the specific case of S. thermophilus, threonine can 
be directly converted into acetaldehyde and glycine by the serine hydroxymethyltransferase (SHMT; 
EC 2.1.2.1). This is an important enzyme involved not only in the formation of glycine and serine but 
also in the turnover of folate in all organisms (Chaves et al., 2002). 
 
1.3.2.3 Proto-cooperation  
S. thermophilus is used together with L. delbrueckii subsp. bulgaricus for yogurt making, leading to 
a complex symbiotic relationship, so called “proto-cooperation” by Hols et al. (2005), sharing the 
same ecological niche: S. thermophilus produces CO2 and formic acid, which stimulate the growth of 
L. delbrueckii subsp. bulgaricus while L. delbrueckii subsp. bulgaricus hydrolyses milk proteins 
releasing peptides and amino acids that improve S. thermophilus growth (Uriot et al., 2017).  
Moreover, Arioli et al. (2017) explained how microbial interactions leading to positive effects are 
classified as mutualistic interactions. They give positive effects on each population’s growth rate and 
size, while the independent growth of the two species in milk led to a slower growth rate and a smaller 
population size. In particular, Arioli et al. (2017) considered that among the LAB involved in dairy 
fermentation processes, urease activity is present only in S. thermophilus.  
Urea hydrolysis increases the catabolic efficiency of S. thermophilus by modulating the intracellular 
pH and increasing the activity of β-galactosidase, glycolytic enzymes, and lactate dehydrogenase. 
Simultaneously, urea hydrolysis results in increases in intracellular (pHin) and extracellular (pHout) 
pH due to the rapid diffusion of ammonia outside of the cell. Consequently, in the presence of urea 
and a urease-positive microorganism (S. thermophilus), urease-negative microorganisms (L. 
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delbrueckii subsp. bulgaricus) share the environmental benefit derived from the release of ammonia 
(local pH increase). To put it briefly, the homolactic fermentation of L. delbrueckii subsp. bulgaricus 
appeared to be boosted by ammonia released from urease activity of S. thermophilus. Urease 
production should be considered an altruistic cooperative trait: it is costly for urease-positive 
individuals but provides a local benefit because other individuals can take advantage of the release 
of ammonia (Arioli et al., 2017).  
 
1.3.2.4 Bacteriocin production 
Antimicrobial activity is one of the main trait of probiotic properties. 
Many studies have characterized several bacteriocins produced by S. thermophilus showing to have 
in vitro inhibitory activities against LAB but also against gram-positive pathogenic strains such as E. 
faecalis, Clostridium botulinum, Staphylococcus aureus, and L. monocytogenes (Fontaine and Hols, 
2008). Some bacteriocin-producing strains could be used in thermophilic starters since not all 
bacteriocins are active against thermophilic lactobacilli (Delorme, 2008). 
Bacteriocins produced by S. thermophilus strains are known as thermophilins, small peptides able to 
inhibit the growth or kill closely related bacteria. Rossi et al. (2013) defined them as “proteinaceous 
compounds” that are thermostable and active over a wide range of pH values, unlike nisin, which is 
not used in acidic foods. Moreover, they are safe because of the GRAS status of S. thermophilus. 
Production of thermophilins represents a significant interest for conservation in the food industry 
because it may limit the proliferation of pathogenic bacteria in dairy products fermented by S. 
thermophilus. However, as a part of probiotic criteria, it is necessary to test whether these bacteriocins 
are produced in the GIT and are effective against pathogenic bacteria in such environment.  
 
1.3.2.5 Exopolysaccharide biosynthesis 
Extracellular polysaccharides are synthesized by a great variety of bacteria, including LAB, and 
specifically main strains of S. thermophilus. Bacterial exopolysaccharides (EPS) can be composed of 
one type of sugar monomer (homopolysaccharide) or several types of monomers 
(heteropolysaccharide). Heteropolysaccharides are synthesized by many LAB, including S. 
thermophilus; indeed, compositional and structural analyses of EPS revealed the presence of 
galactose, glucose, and rhamnose, as well as N-acetyl-galactosamine, fucose, and acetylated galactose 
(Iyer et al., 2010b).  
These polymers may be assembled as capsular polysaccharides, tightly associated with the cell 
surface, or they may be liberated into the extracellular environment (i.e., “ropy” polysaccharide).  
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Although the presence of exopolysaccharide does not confer any direct advantage to growth or 
survival of S. thermophilus in milk, incorporation of EPS or EPS with respective culture in dairy 
foods can improve rheological properties, such as viscosity, stability, and water-binding. All these 
characteristics contribute positively to the mouth-feel, texture, and taste perception of fermented dairy 
products (Angelin and Kavitha, 2020; Rodríguez et al., 2009).  
Starter cultures producing EPS may be used to control syneresis in yogurt. This method is particularly 
widespread in countries where the addition of plant- or animal-derived stabilizers is prohibited or to 
satisfy modern consumer preferences for products with low content of food additives.  
The ability to produce EPS in S. thermophilus is both strain-dependent and significantly affected by 
media and growth conditions (e.g., temperature, carbon: nitrogen ratio, pH). Generally, the amount 
of EPS produced by S. thermophilus in milk may range from 50 mg to 1.5 g/l (Broadbent et al., 2003). 
In nature, bacterial EPS are thought to fulfill diverse functions that may include cell protection against 
toxic environments and other antagonisms, sequestering of essential cations, colonization, and in 
cellular recognition (Broadbent et al., 2003). 
Rodríguez et al. (2009) evaluated the potential antigastritis effect of fermented milks with EPS-
producing S. thermophilus strains using a murine model of chronic gastritis induced by acetyl-
salicylic acid (ASA). ASA is a nonsteroidal anti-inflammatory drug used worldwide as an analgesic 
and antipyretic agent. Furthermore, it is one of the main causes of gastric damage (i.e., gastrointestinal 
complications ranging from dyspepsia and abdominal pain to gastric ulcers) in people having an 
excessive consumption of this drug. This study showed the gastro-protective effect of EPS produced 
by the S. thermophilus strain. Fermented milks with EPS-producing strains on gastric mucosa chronic 
lesions induced by ASA may be used as a safer and natural gastroprotective alternative, since EPS 
could stimulate the immune system and exert an inhibitory effect on ulcer in the host. 
 
1.3.2.6 Biosynthesis of folate 
Folate is an essential component in the human diet involved as a cofactor in many metabolic 
pathways, such as DNA replication and biosynthesis of nucleotides (Sybesma et al., 2003). Folate is 
a water-soluble vitamin, and its deficiency in humans is quite widespread. It is associated with several 
health problems: increased cancer risk in adults and neural tube defects during embryo development 
(Crittenden et al., 2003). The daily recommended intake for an adult varies from 200 µg in Europe to 
400 µg in the United States (Sybesma et al., 2003).  
Therefore, an exogenous supply of folic acid appears essential to prevent nutritional deficiency. 
Recently, on the opposite side, several studies have shown that high intakes of folic acid, the 
chemically synthesized form of folate, in some cases can cause adverse effects (Iyer et al., 2010a). 
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For these reasons, many researchers are looking for novel natural sources to increase concentrations 
of occurring folate variants in foods. Folate is produced by various green plants and by some 
microorganisms; indeed vegetables and dairy products are the main sources of folate for humans. 
Milk is a well-known source of folate, and fermented milk products are reported to contain up to 110 
µg of folate per liter as a result of the production of additional folate by the LAB in the yogurt 
(Sybesma et al., 2003).  
Numerous researchers have reported that the two LAB species in yogurt, L. delbrueckii subsp. 
bulgaricus and S. thermophilus, can synthesize folate, but only the latter is reported to produce high 
quantities, and the majority of this is excreted into milk (Crittenden et al., 2003; Iyer et al., 2010a). 
Tarrah et al (2018), studying eight different strains of newly isolated S. thermophilus, showed that all 
strains increased the amount of folate during growth, concluding that S. thermophilus has a strain-
specific ability for folate production (Tarrah et al., 2018). 
Hence the application of high-folate-producing S. thermophilus strains could lead the question of 
folate deficiency with its natural folate production ability, which can fulfill the daily recommended 
requirement of folate (200 µg) (Iyer et al., 2010b).  
 
1.3.2.7 Treatment of diarrhea 
S. thermophilus has been shown to have positive effects on diarrhea in young children, enterocolitis 
in premature neonates, and inflammatory gut disease (Delorme, 2008).  
Acute diarrhea is a serious cause of infant mortality resulting from viral (rotavirus) or bacterial 
infections in the gut (Uriot et al., 2017).  
In a large study, involving 571 children, Canani et al. (2007) administered five different probiotic 
preparations, testing their effectiveness in reducing diarrhea duration. The median duration of 
diarrhea was significantly shorter (70 hours) in children who received the mix of four bacterial strains, 
including S. thermophilus, than in children who received oral rehydration solution alone (115 hours). 
Antibiotic-associated diarrhea (AAD) is the most common adverse effect of antibiotic therapy, 
occurring in 1/3 of patients (Beniwal et al., 2003).  
Two major forms of AAD have been identified:  
1. No pathogen-related. Pathogenesis may be related to altered SCFAs in the intestine, functional 
disturbance of bile acid metabolism due to alteration of the microflora. 
2. Clostridium difficile-associated diarrhea (10-20% of AAD). Pathogenesis may be related to 
loss of the resistance provided by normal colonic flora. Antibiotics suppress the intestinal 
microflora that control the proliferation of C. difficile. 
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In a trial conducted by Beniwal et al. (2003), 202 adult patients received 227 g of yogurt per day for 
8 days. Results showed that a dietary supplement of yogurt decreased the risk of developing AAD by 
nearly 50% (P = 0.04), and the total number of diarrheal days was 60 in the control group and 23 in 
the yogurt group.  
In conclusion, Beniwal et al. (2003) stated that “during antibiotic therapy, supplementation with 
commercially available yogurt that contains active cultures is a simple, safe, and cost-effective 
method of reducing the occurrence and severity of AAD”. 
 
1.4 Gastrointestinal tract and its microbiota 
Some ecological considerations on the gut flora are necessary to understand the relevance, for human 
health, of the probiotic food concept. 
The human gastrointestinal tract (GIT) is approximately 7 m long, and the gastrointestinal mucosa is 
the largest surface area within the body (approximately 400 m2), with only a single layer of epithelial 
cells separating the contents of the lumen from the internal milieu (Shanahan, 2002). 
The development of human microbiota is a dynamic process, beginning with birth. In the uterus, 
infants grow in a sterile environment. During the first days of life, the intestine becomes inhabited by 
microbes and is characterized by instability. Subsequently, the microbiota will stabilize during breast 
or formula feeding. The fecal flora of breastfed infants is dominated by Bifidobacterium and 
Ruminococcus, while formula-fed infants have a more complex microbiota with enterobacterial 
genera, Streptococcus, Bacteroides, Clostridium, Bifidobacterium, and Atopobium (Salminen et al., 
1998). 
The next great changes in the composition of the intestinal microbiota come with the introduction of 
solid food: a more stable community similar to the adult microbiota becomes established after 
weaning (at 2-3 years of age) (Power et al., 2014). After this, only relatively small changes take place, 
and a child has an adult-like microbiota by approximately two years of age.  
The microbes that are present in the microbiota have been distinguished into two categories 
(Zoetendal et al., 2008):  
• individual core: continuously present in an individual’s microbiota, representing the stable 
colonizers of the healthy individual. It is determined partly by the host genotype, by initial 
colonization at birth via vertical transmission, and by dietary habits (Guarner et al., 2017); 
• common core: a limited number of microbial phylotypes shared by different people. 
During adult life, the stability of the composition of the intestinal microbiota at the species level is 
relatively common, while stability at the level of bacterial strains may be less common (Mccartney 
et al., 1996). This relative stability is reduced in old age. Furthermore, the microbiota is then driven 
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by a series of complex and dynamic interactions. The presence of major stressors, as environmental 
stresses, medication, extreme based diets, and most noticeably antibiotic treatment may lead to 
perturbations of the intestinal microbiota.  
The intestinal mucosa is said to contain more nerve endings than any other tissue in the body. Severe 
and prolonged states of stress have been shown to have profound effects on the individual, causing 
gut-derived sepsis. It is considered as a systemic inflammation caused by the release of 
norepinephrine into the intestinal lumen, leading to changes in the beneficial bacteria and alterations 
of the phenotype of the potentially pathogenic microorganisms, which become considerably more 
virulent and sometimes life-threatening (Alverdy et al., 2003). 
 
The microbial content of the GIT changes along its length, ranging from a narrow diversity and low 
numbers of microbes in the stomach to a wide diversity and high numbers in the large intestine (Power 
et al., 2014). The adhesion capacity, enzymes, and metabolic activity of the GIT also contribute 
largely to this variation of bacteria (Patel et al., 2016). Furthermore, the microbiota’s composition at 
the mucosal surface differs from that within the lumen and faeces, and the ratio of anaerobes to 
aerobes is lower at the mucosal surfaces than in the lumen (Shanahan, 2002). 
Microbial cells are present in minimal numbers in the stomach and proximal small intestine 
(duodenum and jejunum) (Figure 1.5). They can not colonize these regions because of the acidic pH 
(stomach) and relatively rapid flow of the digesta (duodenum and jejunum). The total bacterial count 
in gastric contents is usually below 103 CFU/ml, while in the small intestine, numbers range from 
Figure 1.5 - Bacteria density increases in the jejunum and in the ileum from the stomach and duodenum; in 
the large intestine, colon-residing bacteria achieve the highest cell densities recorded for any ecosystem 
(O’Hara and Shanahan, 2006). 
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approximately 104 CFU/ml contents to about 106-107 CFU/ml at the terminal ileum region (Tannock, 
1999). The main factors limiting growth in the small bowel are the rapid transit of contents and bile 
and pancreatic juice secretion.  
The human large intestine is a complex, heavily populated, and diverse microbial ecosystem. Several 
hundred species of bacteria are usually present. The majority are strict anaerobes, with typical 
numbers of about 1011-1012 CFU for every gram of colonic content (Salminen et al., 1998).  
Resident bacteria, the microbiota, outnumber human somatic and germ cells 10-fold (O’Hara and 
Shanahan, 2006) and in its entirety is estimated to contain 150-fold more genes than the human 
genome (Power et al., 2014). The entire human intestine is colonised by 1013 to 1014 microorganisms, 
the vast majority of which belong to the phylum Firmicutes (including Clostridium, Enterococcus, 
Lactobacillus and Ruminococcus) and to the phylum Bacteroidetes (including Bacteroides and 
Prevotella genera), which constitute over 90% of the totality known intestinal microorganisms and 
30% of the total anaerobic population. The others are mainly Actinobacteria, Proteobacteria, 
Verrucomicrobia, and Fusobacteria (Guarner et al., 2017). Although bacteria predominate, archaea 
and eukarya are also represented (O’Hara and Shanahan, 2006).  
 
1.4.1 Functions of intestinal microbiota 
“The flora has a collective metabolic activity equal to a virtual organ within an organ” (O’Hara and 
Shanahan, 2006). 
Co-evolution of the host and flora implies mutually beneficial interactions, defined as a symbiotic 
relationship by Guarner et al. (2017); hence any variation of these balance, known as dysbiosis, may 
lead to detrimental responses and chronic inflammatory disease (Shanahan, 2002).  
Symbiotic relationships can be described as (Hill and Artis, 2010):  
• mutualistic: both species gain a benefit from the interaction; 
• parasitic: one member benefits and the other is harmed; 
• commensal: one member benefits, and the other is unaffected. 
The microbiota offers many benefits to the host through a range of physiological, structural, and 
metabolic functions such as shaping the intestinal epithelium, harvesting energy, protecting against 
pathogens, and regulating host immunity (Thursby and Juge, 2017). 
The main protective function of intestinal bacteria is to provide a fortification of barrier role that 
prevents pathogenic bacteria from invading and colonizing the GIT by competitive exclusion, such 
as the occupation of attachment sites, competition for receptors, consumption of nutrient sources, and 
production of antimicrobial substances (e.g., bacteriocins, lactic acid) (Sekirov et al., 2010). 
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The primary metabolic activity of the large-intestinal microflora is the breakdown, through 
fermentation, of carbohydrates, not digested in the upper gut, to SCFAs, which are then rapidly 
absorbed (Salminen et al., 1998). In this way, the host can salvage energy from indigestible food 
components that would otherwise be lost by excretion from the digestive tract.  
The major substrates available for fermentation are starches that enter the colon (resistant starch), the 
non-starch polysaccharides (e.g., cellulose, hemicelluloses, pectins, and gums), and oligosaccharides 
(Cummings and Macfarlane, 1997). By producing SCFAs such as acetate, propionate, and butyrate, 
the resident bacteria positively influence intestinal epithelial cell differentiation and proliferation, and 
mediate other metabolic effects. In addition, gut bacteria are involved in vitamin synthesis (especially 
vitamins B12 and K) (Woodmansey, 2007) and modulation of fat deposition (O’Hara and Shanahan, 
2006). 
Regarding metabolic effects, the microbiota shapes the development of the immune system, and the 
immune system in turn shapes the composition of the microbiota (Nicholson et al., 2012). The sheer 
number and the large intestinal surface area of intestinal bacteria present a persistent threat: they pose 
a constant risk of invasion (Thursby and Juge, 2017). The opportunistic invasion of host tissue by 
resident bacteria can break down the symbiotic host-microorganism relationship and contribute to 
pathologies such as bacteraemia or chronic inflammation. To maintain homeostasis, the GIT limits 
the host immune system’s exposure to the microbiota by recruitment of a multifactorial and dynamic 
intestinal barrier. The barrier comprises several integrated components including physical (the 
epithelial and mucus layers), biochemical (enzymes and antimicrobial proteins), and immunological 
(IgA and epithelia-associated immune cells) factors (Hooper and MacPherson, 2010). 
The microbiota strongly influences the host immune system, and it contributes to the development 
and differentiation of the mammalian immune system. Different studies have been proposed using 
germ-free (GF) animals, mostly mice, to understand the connections between intestinal bacteria and 
stimulation of immune system. Different effects on the structural and functional development of the 
immune system have been revealed comparing GF mice and “microbiota-colonized animals”. The 
most frequently detected are (Maslowski and MacKay, 2011; Maynard et al., 2012; Nicholson et al., 
2012; Sekirov et al., 2010):  
• GF animals contain abnormal numbers of several immune cell types and immune cell 
products; 
• deficits in local and systemic lymphoid structures and tissues development, such as the spleen, 
thymus, and lymph node in GF mice; 
• the above-mentioned structural abnormalities have been detected mostly near the mucosal 
interface, suggesting that interactions with specific microbes communities directly modulate 
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the development of these GALTs. Different types of GALT known as isolated lymphoid 
follicles, Peyer’s patches of the distal ileum and mesenteric lymph nodes are minimally 
present and smaller in GF mice;  
• GF mice showed an irregular intestinal epithelial cell morphology that includes longer villi 
and shorter crypts in comparison with that observed in mice with natural microbiota; 
• the hyperactivity of innate immune response in GF mice, such as macrophages, presents 
higher concentrations of lysosomal enzymes. 
These different studies demonstrate that the microbiota participates in the maturation of the immune 
system and suggests that specific events in association with microbial colonization may be important 
in the development of a normal immune system in a healthy individual (Gensollen et al., 2016). 
Widespread antibiotic administration, while working on targeted infections, perturbs the intestinal 
microbiota. Deep 16S rDNA sequencing, performed after antibiotic treatment, has revealed dramatic 
and long-term changes to the intestinal microbiota that have implications for immune defense (Brandl 
et al., 2008; Ubeda and Pamer, 2012). Regarding this, Bohnhoff et al. (1954) revealed that 
streptomycin administration alters the gut microbiota and contributes to mice susceptibility to 
infection with Salmonella spp. Similarly, ≤ 101 Salmonella enteritidis were sufficient to kill GF 
guinea pigs, whereas 109 bacteria were required to kill animals with complete intestinal microflora 
(Freter, 1955). 
Furthermore, this fragile balance between microbiota and host can be affected by diet. Extreme 
“animal-based” or “plant-based” diets result in alterations of the gut microbiota in humans (Thursby 
and Juge, 2017). Foodborne microbes from both diets transiently colonized the gut, including 
bacteria, fungi, and even viruses (David et al., 2014). A “plant-based diet” is rich in grains, legumes, 
fruits, and vegetables, while an “animal-based diet” comprises meats, eggs, and cheeses. Comparing 
these two different diets, the latter one resulted in significantly lower levels of the products of 
carbohydrate fermentation, a higher concentration of the products of amino acid fermentation, and 
increased expression of genes associated with degradation of polycyclic aromatic hydrocarbons, 
which are carcinogenic compounds produced during the charring of meat (Turnbaugh et al., 2009). 
Due to the fastidious nature of many probiotic bacteria, especially S. thermophilus, survival in 
sufficiently amount during passage through the above-mentioned environment of human GIT remains 
a major challenge for effective delivery of these beneficial bacteria (Annan et al., 2008).  
 
1.4.2 S. thermophilus survival in the gastrointestinal tract conditions 
The ability to survive the GIT transition is considered a key feature of probiotic strains to preserve 
their expected health-promoting effects (FAO/WHO, 2006) and to be assessed most studies proposed 
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the recovery of viable cells in fecal samples after oral administration. The concentration of probiotics 
needed to obtain a health effect is estimated as ≥ 106 CFU/ml in the small bowel and ≥ 108 CFU/ml 
in the colon (Minelli and Benini, 2008). 
Martinović et al. (2020) analyzed different studies, and suggested that the recovery and identification 
of S. thermophilus is not always correctly performed. Primarily, other Streptococcus spp. that inhabit 
the human GIT could interfere, or could be misidentified, with the correct identification of S. 
thermophilus in stool samples. In particular, S. salivarius has been recovered from fecal samples of 
infants, thus revealing that this specie is one of the primary inhabitant of the intestinal microbiota 
(Favier et al., 2002; Kawamura et al., 1995). Moreover, molecular tools developed for the 
identification of S. thermophilus are based on species-specific polymerase chain reaction (PCR) 
primers targeting the 16S rDNA gene sequence. In a comparative genomic analysis performed by 
Delorme et al. (2015), the 16S rDNA gene sequence has been found not specific enough because of 
a high identity among those sequences in S. thermophilus, S. salivarius and S. vestibuilaris species 
(99.8% between S. thermophilus and S. salivarius; 99.6% between S. thermophilus and S. 
vestibularis) (Delorme et al., 2015). 
Moreover, contradictory results from different studies showed by Martinović et al. (2020) on the 
ability of S. thermophilus strains to survive GIT conditions may be due to differences in the absolute 
number of live cells administered (Fenster et al., 2019).  
Also, viability has been classically determined by plate counting; however it can shows 
disadvantages, such as an underestimation of viable bacteria due to the irregular distribution of 
microorganisms in the sample and the loss of culturability under stress conditions (García-Hernández 
et al., 2012a). 
In conclusion, Martinović et al. (2020) recommended to create guidelines and protocols for the correct 
recovery and identification from stool samples of orally administered probiotics. In this sense, many 
in vitro and in vivo (human trial) studies have been performed with contradictory results, as shown 
below.  
 
1.4.2.1 In vitro experiments 
The Expert Consultation (2001) stated that “proper in vitro studies should establish the potential 
health benefits of probiotics prior to undertaking in vivo trials” (FAO/WHO, 2006). In vitro 
experiments contribute to a better understanding the influence of pH and bile salts concentrations on 
bacteria survival and physiology.  
Numerous in vitro multi-compartmental models, which simulate different parts of the human 
gastrointestinal tract, have been developed to study the survival rate of potential probiotic strains. For 
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instance, Uriot et al. (2016) proved the survival of S. thermophilus using the dynamic TIM model 
(TNO gastrointestinal model), which closely simulates the physicochemical conditions found in the 
human stomach and small intestine, such as body temperature, changes in pH, transit time, sequential 
supply of digestive enzymes and bile salts as well as passive absorption of nutrients and water (Uriot 
et al., 2016).  
Junjua et al. (2016) tested 30 S. thermophilus strains of different origins for their capacity to resist 
stresses representative of the GIT and to adhere to enterocytes. Resistance to the acidic environment 
was determined at pH 2 and 4. The first pH value corresponds to the stomach pH observed during 
inter-prandial phases, whereas the second is often used to determine the in vitro capacities of survival, 
and it is considered more realistic since bacteria are generally incorporated in the food-bolus which 
buffers the pH of the stomach and protects them against direct exposure to extreme pH conditions 
(Both et al., 2010). At pH 2 no growth was detected for all of the strains, whereas all of the strains 
resisted pH 4. This outcome is in accordance with the ability of the tested strains to remain alive in 
milk at the end of fermentation when the pH is about 4.2-4.3 (Galia et al., 2009). 
Zhang et al. (2020) selected ten different strains of S. thermophilus, showing strong resistance to 
simulated gastric juice: the survival rates of all strains were at a high level (> 95%), and there was no 
significant difference when pH was 5.0. Since these strains have been isolated from the pickle, it was 
completely reasonable that they were well adapted to pickle acid conditions with a pH of about 3.5 
(Zhang et al., 2020). 
Regarding the resistance to bile salt, thus conditions of the small intestinal tract, a high strain-
dependent was observed in Junjua et al. (2016) and Iyer et al. (2010a). Adhesion property of a 
probiotic to intestinal mucosa is also regarded as a prerequisite for probiotics. In vitro models are 
based on adhesion to tissue culture cell lines such as Caco-2 and HT-29, which resemble the 
enterocytes of human small intestine, and to human intestinal mucus (Fernández De Palencia et al., 
2008). In the study performed by Junjua et al. (2016) only 4 out of the 30 S. thermophilus strains 
tested showed an adhesion percentage higher than 8%. 
Kebouchi et al. (2016) have investigated the effect of different concentrations of bile salts on S. 
thermophilus LMD-9 strain and concluded that it was resistant to bile salts up to 3 mM, and it was 
able to adhere to different intestinal epithelial cells (IECs) tested in vitro. 
 
1.4.2.2 Human trials 
To investigate probiotics survival, in particular S. thermophilus, in human GIT, human trials are the 
golden standard. However, these studies are costly and heavy to perform. FAO/WHO (2006) 
suggested that performing randomized, double-blind, placebo-controlled human trials to establish the 
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efficacy of the probiotic product; further, they have to be repeated by more than one recognized center 
for confirmation of results. 
For example, Mater et al. (2005) investigated the survival of S. thermophilus and L. delbrueckii subsp. 
bulgaricus by culture analysis of feces from healthy subjects over a 12-day period of fresh yogurt 
intake containing 7.8 x 108 CFU/ml viable rifampin- and streptomycin-resistant strains of S. 
thermophilus. During the period of intake, viable S. thermophilus cells were recovered, by standard 
plating, from 32 out of 39 fecal samples (82%) at levels between 4.0 x 102 and 3.5 x 106 CFU/g of 
feces, suggesting that they can survive transit in the gastrointestinal tract (Mater et al., 2005). 
Afterward, Elli et al. (2006) again confirmed that S. thermophilus could be retrieved from human 
feces of 20 healthy volunteers after commercial yogurt consumption for 1 week, although S. 
thermophilus has been detected from only one volunteer on day 7. They concluded that “we cannot 
exclude the possibility that a prolonged ingestion period or a larger amount of ingested yogurt, could 
positively affect the rate of S. thermophilus recovery from fecal samples” (Elli et al., 2006). 
Later on, García-Hernández et al. (2012b) detected viable cells of S. thermophilus, especially when 
the intake of yogurt was the highest of the study, in 30% of the total number of samples analyzed by 
applying a direct viable count-fluorescence in situ hybridization (DVC-FISH) method to fecal 
samples. During consumption, the concentration of viable S. thermophilus in the feces rapidly 
increased to reach a plateau. In contrast, in the post-administration period, one or two weeks after 
suspension of yogurt consumption, there was a significant decrease in the number of positive samples, 
and S. thermophilus counts dropped below the detection limit (García-Hernández et al., 2012b).  
Similarly, Venturi et al. (1999) described the recovery of S. thermophilus after oral administration of 
a multi-strain probiotic preparation, containing one strain of S. thermophilus, by standard plating, 
concluding that it is capable of colonizing the gut and the duration of colonization was evident only 
during the drug’s administration (Venturi et al., 1999). 
Subsequently, Brigidi et al. (2003) detected S. thermophilus from human fecal samples after 3 days 
of intake of the pharmaceutical preparation VSL#3 (VSL pharmaceuticals Inc., Fort Lauderdale, 
USA) or yogurt, and it persisted for 6 days after the treatment suspension. Similarly, Mimura et al. 
(2004) demonstrated, through PCR analysis, that after administration of VSL#3, S. thermophilus was 
detected at higher levels in all patients treated.  
The above-mentioned studies showed that S. thermophilus can survive the passage through the human 
GIT and can be detected in the feces of volunteers after consumption. However, the count of S. 
thermophilus decreased after administration, compared with other LAB that can be found longer in 
the feces (Venturi et al., 1999). 
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Contradictory results have been proposed by Del Campo et al. (2005). One hundred fourteen young 
volunteers took part in an experiment, with daily consumption of commercially produced fresh yogurt 
(375 g). Detection of yogurt LAB, especially S. thermophilus, in total fecal DNA by bacterial culture 
and PCR assay was consistently negative, suggesting that a substantial multiplication of yogurt 
bacteria in the small intestine is not expected to occur. The researchers concluded that “the presumed 
probiotic effect of yogurt should depends on the frequency of ingestion” (Del Campo et al., 2005). 
It must be noted that none of these studies in vivo has investigated the survival of the bacterium when 
ingested alone (only within a yogurt or a preparation of different strains of probiotic bacteria), and 
survival to GIT conditions is strictly strain specific.  
As reported above, according to the guidelines suggested by the FAO/WHO Expert Consultation, to 
be effective for use in foods, probiotic cultures must be capable of surviving passage through the 
digestive tract, possess the capability to proliferate in the gut, withstand processing conditions and 
survive in sufficient numbers (108 CFU/g) in the product during shelf-life storage (Minelli and Benini, 
2008).  
Several methods have been proposed to enhance the viability and to increase the resistance of 
sensitive probiotic microorganisms against adverse conditions, such as the selection of acid- and bile- 
resistant strains, stress adaptation system, incorporation of micronutrients (peptides and amino acids), 
and microencapsulation (Anal and Singh, 2007; Rokka and Rantamäki, 2010).  
 
1.5 Microencapsulation technology  
Microencapsulation (ME) is defined as the “technology of packaging solids, liquids or gaseous 
materials (active agent) in small capsules (wall material) that can release their contents at controlled 
rates under the influences of specific conditions over prolonged periods of time” (Anal and Singh, 
2007). Also, encapsulation has been defined as a mechanical or physicochemical process to entrap 
active sensitive agents within a carrier material and as a useful tool to improve the delivery of 
bioactive molecules (e.g., antioxidants, minerals, vitamins, phytosterols, lutein, fatty acids, lycopene) 
and living cells (e.g., probiotics) into foods (Nedovic et al., 2011). 
This technology is useful for different sectors: 
• food industry: to encapsulate ingredients for functional food and nutraceuticals. The use of 
sweeteners encapsulated such as aspartame and flavours in chewing gum are well known 
(Gibbs et al., 1999); 
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• pharmaceutical sector: for drug and vaccine delivery. For example, Anal and Stevens (2005) 
develop multilayer beads, obtained through ionotropic gelation, for controlled delivery and 
release of the antibiotic ampicillin; 
• agriculture, textiles, and paper industries (Timilsena et al., 2020). 
In the food industry, the microencapsulation process can be applied for a variety of reasons, which 
have been summarized by Champagne and Kailasapathy (2008) and Rokka and Rantamäki (2010) as 
follows: 
• stabilize the active content or food ingredients; 
• provide barriers between sensitive bioactive materials and the environmental stressors. For 
instance, the capsules may allow the content pass through the adverse pH conditions of the 
stomach or can protect from light, cold shock (induced by process conditions such as deep 
freezing and freeze-drying), and heat shock (caused by process conditions such as spray 
drying); 
• prevent reaction with other components in food products such as oxygen or water, and 
therefore control the oxidative reaction; 
• provide a sustained or controlled release (both temporal and time-controlled release); 
• mask bad flavours, colours, or smelling, such as unpleasant feelings during eating (e.g., bitter 
taste and astringency of polyphenols); 
• extend the shelf-life and improve stability in final products and during processing; 
• protect components against nutritional loss while increasing their bioavailability; 
• immobilize cells or enzymes in food processing applications, such as fermentation and 
metabolite production processes, or improve the homogeneous distribution of cells throughout 
the product; 
• modification of the physical characteristics to facilitate handling (e.g., converting the liquid 
active agent into a powder). 
A microcapsule consists of a small vesicle or particulate with a semipermeable, spherical, thin, and 
strong membrane surrounding a solid/liquid core size (Fang and Bhandari, 2010). Beads without 
coating can also be considered as microcapsules in a broad sense.  
As particle size affects texture, thus the sensory properties of food products, the capsules have to 
range from a diameter of few microns to several millimeters (Wandrey et al., 2010). 
The encapsulated substance can be pure material or a mixture, and it is often called the core, fill, 
active, internal, or payload phase. On the other hand, the packaging material is called coating, wall, 
capsule, membrane, carrier, shell, external phase, or matrix (Fang and Bhandari, 2010; Jan Zuidam 
and Shimoni, 2010). For example, in nature, eggshells, plant seeds, bacterial spores, skin, and 
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seashells can be considered natural capsules, which allow protection of the contents from the 
environment while allowing small molecules to pass in and out of the membrane (Gibbs et al., 1999). 
Many morphologies can be distinguished with encapsulation technology, but two major types of 
encapsulates are more commonly identified (Schrooyen et al., 2001) as shown in Figure 1.6: 
• mononuclear capsules or reservoir type: which have a single active core enveloped by a shell. 
This type is also called single-core, mono-core, or core-shell type; 
• aggregates or matrix type: which have many cores, in the form of small droplets or more 
homogeneously distributed over the encapsulate, embedded in a matrix.  
 
  
1.5.1 Microencapsulation of probiotics 
Nowadays, probiotics are the driving force in the design of functional foods, particularly in dairy 
products. Therefore, it is essential to improve cell survivability during GIT passage, and the 
formulation of these probiotics into microcapsules seems to be a promising emerging solution and an 
opportunity to control the release of these cells in their target, the gut (Cook et al., 2012). De Vos et 
al. (2010) claimed that microencapsulation of many probiotics may be mandatory for achieving the 
promised health benefits.  
However, probiotics present two limiting factors when considering encapsulation: the size (typically 
between 1 and 5 µm of diameter), which immediately excludes nanotechnological approaches of 
encapsulation, and the cells must be kept alive (Champagne and Fustier, 2007). This latter point is 
crucial in selecting the appropriate probiotic encapsulation technology. 
According to Anal and Singh (2007), the ME of probiotics and the addition into foods and beverages 
offers many technological benefits, beyond the improvement of viability of cells (Table 1.4).  
The number of cells in beads or microparticles can be quantified, allowing the dosage to be readily 
controlled, and the narrow size and shape distribution can confer consistent performances (e.g., 
metabolite exchange) (De Prisco et al., 2017). 
Figure 1.6 - Two major forms of encapsulation: mononuclear capsule or reservoir type (left) and aggregate or 
matrix type (right) (Fang and Bhandari, 2010). 
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Moreover, cryo- and osmo-protective components can be incorporated into the matrix, enhancing 
cells’ survival during processing and storage.  
In addition, the coating layer can have desirable dissolution properties: microcapsules can be 
engineered to release the active core, which permits delayed release of the cells or release upon, for 
example, a change in pH (Anal and Stevens, 2005). There are many different ways of opening 
microcapsules, including heat shock fracture by the dissolution method, solvation, and applying 
suitable pressure (Riaz and Masud, 2013). Release properties are mainly based on particle size, shape, 
and material characteristics (Burey et al., 2008).  
Sultana et al. (2000) reported that alginate concentration and capsule size can affect the survivability 
of probiotic: they are directly proportional to cell viability, whereas the initial cell numbers do not 
affect bacterial death rates. According to Chan and Zhang (2005), the cell release in alginate-based 
microencapsulation is primarily due to the erosion of the alginate gel layer. In particular, increasing 
the β-D-mannuronic acid (M) content of alginate, the gel structure formed becomes softer, more 
elastic, but less porous, and it can be dissolved more easily (Tønnesen and Karlsen, 2002).  
A coating material may also be designed to open in the specific areas of the body: since the intestine 
provides the right conditions for probiotics to survive and multiply, release of cells into this site leads 
to probiotics settlement and activity. Mortazavian et al. (2007) found that when the capsules are 
opened in the small intestine, the released cells are expected to arrive in the large intestine. 
Regarding the synbiotic interactions between probiotic bacteria and prebiotic, Etchepare et al. (2015) 
reported that the combination of alginate with prebiotics offers enhanced protection for probiotics in 
food systems. This can be explained by the fact that prebiotics form three-dimensional microcrystals 
networks that interact together, forming small aggregates that contribute to better protection for 
probiotics. The prebiotics applied in co-encapsulation (probiotic and prebiotic together) technology 
are fructooligosaccharides, inulin, and resistant starches (Etchepare et al., 2015). Their application is 
useful especially when invasive techniques that can decrease cell viability, such as spray or freeze-
drying are used for the microencapsulation (De Prisco and Mauriello, 2016). 
According to Sultana et al. (2000), co-encapsulation of probiotic bacteria with prebiotic improved 
entrapping of viable bacteria as compared to bacteria encapsulated without the prebiotic molecule. In 
particular, Hi-Maize starch (resistant starch) was used at different concentrations in the encapsulation 
procedure to provide prebiotics to the encapsulated probiotic bacteria. In conclusion, starch and 
alginate have a synergic interaction in gelation and prebiotic may help in providing additional 
protection to the entrapped bacterial cells (Sultana et al., 2000).  
In general, for encapsulation, probiotic bacteria are grown in their optimal culture conditions, after 
which they are centrifuged and used in suspension form or as freeze-dried powder (Rokka and 
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Rantamäki, 2010). The ideal microencapsulated probiotic as a commercial product would either be a 
dry powder, with ease of storage and long shelf-life, or a wet gel with long-term stability in a food 
product (Cook et al., 2012). 
Materials used for encapsulation of probiotic must be food-grade, biodegradable, and able to form a 
barrier between the internal phase and its surroundings (Nedovic et al., 2011). The most commonly 
used constituents in encapsulation of probiotic bacteria include polysaccharides originating from 
seaweed (κ-carrageenan, alginate), other plants (starch and its derivatives, gum arabic), bacteria 
origin (gellan, xanthan), and animal proteins (caseins and whey proteins, gelatin) (Rokka and 
Rantamäki, 2010). 
 
Table 1.4 - Beneficial effects derived from the microencapsulation of lactic acid cultures in alginate matrices. 
Benefits are gained both for the production of probiotics and their use in nutraceutical and food applications 
(Champagne and Fustier, 2007; Mortazavian et al., 2007). 
Benefit  Product 
Facilitates the production of oxygen-sensitive cultures  Dried probiotic culture  
Facilitates the recovery of centrifugation-sensitive cultures  Dried probiotic culture  
Facilitates the recovery of high EPS-producing cultures  Dried probiotic culture  
Less contamination problems Dried probiotic culture  
Cultures can be air-dried Dried probiotic culture 
Improved survival on exposure to gastric solutions  Nutraceutical  
Improved survival on exposure to bile solutions  Nutraceutical  
Improved stability during storage in dried form  Nutraceutical 
Improved acidification rate  Dried sausages  
Improved survival on heating  Biscuits, powder 
Improved survival on freezing Ice cream, milk-based medium, cranberry juice  
Improved retention in the finished product  Cheese 
Protection against bacteriophages  Fermented milks  
Protection against yeast contaminants  Fermented milks 
Improved survival during storage Yoghurt, mayonnaise, milk 
 
 
The techniques most commonly used in the microencapsulation of probiotics are emulsion, extrusion, 
and spray drying. Other less common methods are adhesion to starch and matrix encapsulation.  
 
1.6 Microencapsulation methods 
There are several techniques available for encapsulation of food compounds. They differ depending 
on the nature of the core and final use of capsules obtained.  
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First of all, to select an encapsulation system, it is needed a physicochemical understanding of the 
encapsulation mechanisms: possible interaction of the active core with the external phase, stability of 
the payload phase, and release actions from the matrix (Timilsena et al., 2020). 
In general, three steps are required:  
1. formation of the wall around the core material: primarily making droplets of the active (in gas, 
liquid, or powder form) and subsequently surrounded by carrier material in a gas or liquid 
phase via different physic-chemical processes; 
2. ensuring that leakages, fissures do not occur; 
3. ensuring that undesired materials are kept out. 
Encapsulation techniques applied to the food industry include spray-drying, fluid bed coating, spray-
chilling or spray cooling, injection, extrusion, emulsification, coacervation, co-extrusion, inclusion 
complexation, liposome entrapment, centrifugal extrusion, encapsulation by a rapid expansion of 
supercritical fluid, freeze- or vacuum drying, and nanotechnological approaches (Timilsena et al., 
2020).  
 
1.6.1 Emulsion technique 
Emulsification is defined as a process of dispersing one liquid, in which the active component is 
included, in a second immiscible one. It is also known as internal ionic gelation or a two-phase 
system. In most cases, the encapsulating agent is a molecule already present in the food (Augustin 
and Hemar, 2009). 
In this method, a small volume of cell/polymer slurry (dispersed or discontinuous phase) is added to 
the large volume of vegetable oil (continuous phase) such as sunflower, soy, corn, or light paraffin 
oil (Iravani et al., 2015). Subsequently, calcium chloride is added to the emulsion of water droplets 
of alginate (slurry) solution and active in vegetable oil. This results in the “break-up” of the emulsion, 
and microbeads are formed by the gelation of the alginate droplets (Jan Zuidam and Shimoni, 2010). 
This technique has been successfully applied for the microencapsulation of LAB. 
As an example, Sheu and Marshall (1993) developed a method to entrap bacteria using a two-phase 
(water/oil) system. The encapsulation material, 3% of sodium alginate, has been first mixed with the 
microbial cells and suspended in an oil bath containing 0.2% Tween 80 as the emulsifying agent. The 
water/oil emulsion has been broken by adding CaCl2, forming calcium alginate beads containing the 
cells (Sheu and Marshall, 1993).  
The emulsion technique has the benefit of producing tiny (25 µm-2 mm) microcapsules, representing 
an advantage in laboratory-scale production, as particular equipment is not necessary to produce these 
tiny particles (Mokarram et al., 2009).  
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However, this technique is more expensive than the extrusion method due to the need to use vegetable 
oil for emulsion formation (Mortazavian et al., 2007). 
 
1.6.2 Extrusion technique 
The extrusion technique is also called droplet or external ionic gelation.  
The method consists of the following stages (Nedovic et al., 2011):  
• preparation of hydrocolloid solution/aqueous solution of polymer (most often this is 0.6-3 w/v 
% sodium alginate) and active/core (e.g., probiotic cells); 
• extrusion of the cell suspension through syringe needle or nozzle in a way that the resulting 
droplets directly drip into the hardening solution/gelling bath (in case of alginate, a gelling 
bath is 0.05-1.5 M CaCl2 solution). 
Generally, the CaCl2 coagulation solution consists of multivalent cations (e.g., calcium in the form 
of calcium chloride).  
The dripping tool can be simply a pipette, a syringe, a vibrating nozzle, a spraying nozzle, jet cutter, 
or atomizing disk. However, the choice of the utensil is crucial since the nozzle or needle size used 
to drip the solution affects the size of the microcapsules, and the survival of cells in beads is higher 
with larger beads. Also, the diameter of the obtained beads and hence the cells’ survival rate is found 
to increase as the concentration of sodium alginate increases (Lee and Heo, 2000).  
Moreover, the size of the droplets depends upon the flow rate of the solution, and the viscosity of the 
solution, besides the distance between the syringe and the solution of calcium chloride (Burey et al., 
2008). Generally, the diameter of capsules obtained with this method ranges from 500 μm to 3 mm, 
and therefore the microcapsules are larger than those formed in the emulsion method (Mortazavian 
et al., 2007). 
In general, it is a simple and inexpensive method with gentle operations, which makes cell injuries 
minimal and results in more uniformly shaped microcapsules than achieved by the emulsion 
technique.  
Extrusion technologies have many advantages for the encapsulation of microbes. It is relatively soft, 
and the procedure does not involve deleterious solvents. Also, the extrusion technique promotes a 
relatively high viability of probiotic cells (Iravani et al., 2015; Mortazavian et al., 2007; Rokka and 
Rantamäki, 2010). Extrusion technologies are also applied for flavors, enzymes, and proteins (De 
Vos et al., 2010). 
One possible disadvantage is the difficulty to be scaled up. This procedure may not be applied for 
large-scale production, and it may be suitable only for laboratory-scale processes. Despite this, multi-
nozzle arrays have been developed by industry to scale up extrusion operations (Cook et al., 2012). 
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Encapsulating materials used in extrusion technology include gelatin, sodium alginate, carrageenan, 
starches, cellulose derivatives, gum acacia, fats and fatty acids, waxes, and polyethylene glycol 
(Wandrey et al., 2010). 
 
1.6.2.1 Alginate 
The most common encapsulation agent is alginate due to its particularly mild gelling conditions, 
GRAS status, and lack of toxicity. Alginates or algin is a generic term for the salts and derivatives of 
alginic acid which are derived primarily from marine brown algae or bacterial sources (Cook et al., 
2012). They are commercially available as Mg2+,Ca2+,Sr2+,Ba2+, and Na+ salts (Gombotz and Wee, 
2012). Sodium alginate is an example of water-soluble alginate (Wandrey et al., 2010). 
Alginates are copolymer, structurally formed by linear unbranched natural polysaccharides made up 
of β-D-mannuronic (M) and α-L-guluronic acid (G) residues joined linearly by (1-4)-glycosidic 
linkages (Annan et al., 2008). Notably, due to the presence of carboxylic acid groups on both 
monomers, alginate carries a negative charge above its pKa (3.3-3.5) (Cook et al., 2012).  
The intramolecular electrostatic repulsion between the contiguous negative charges of each monomer 
forces alginate molecules into an extended random coil conformation. Even at low concentration, 
alginate solutions present high viscosity due to this coil conformation (Wandrey et al., 2010). 
The ability of alginate to form gels is due to the interactions between divalent cations (e.g., calcium, 
cadmium, or zinc) and four guluronic acid (G) residues, forming what has been described as an “egg-
box structure” (Etchepare et al., 2015). In other words, the polymer chain adopts a characteristic 
zigzag shape, as shown in Figure 1.7. This mechanism is known as ionotropic gelation.  
The gelation occurs when it is produced a zone of union (interchain association) between the carboxyl 
groups of two pairs of two consecutive acid α-L-guluronic (G) units, each pair belonging to different 
alginate chains, through the coordination of a Ca2+ cation forming a stable junction zone (Etchepare 
et al., 2015; Sikorski et al., 2007). This linkage process is known as cross-linking (Gombotz and Wee, 
2012). The importance of the G units in this process is highlighted by the fact that the gel strength is 





Gelatin differs from the hydrocolloid (alginate) discussed above in that it is derived from an animal 
protein, collagen, via controlled acid or alkaline hydrolysis (Burey et al., 2008). Common gelatins 
are mainly extracted from bovine (cow) and porcine (pig) sources, but other origins such as piscine 
(fish) and poultry may be used. These gelatins vary widely in their size and charge distribution 
(Armisen and Galatas, 2009). 
Gelatin consists of 14% moisture, 84% protein, and 2% ash (Burey et al., 2008). The protein fraction 
consists of a heterogeneous mixture of single- or multi-stranded polypeptides, in which amino acids 
such as glycine, proline, and hydroxyproline are present in the most abundance (Wandrey et al., 
2010). The general amino acid sequence is glycine-X-Y triplets, where X and Y are frequently proline 
and hydroxyproline amino acids (Figure 1.8). This repeating structure occurs over the entire polymer 
chain forming the characteristic triple helical structure in gelatin (Burey et al., 2008). In gel formation, 
triple helical segments form the basis for cross-linking and three-dimensional network formation 
(Figure 1.9): the coils undergo a coil-to helix transition, leading to thermoreversible gelation 
(Wandrey et al., 2010). It does not form beads but could still be considered as material for 
microencapsulation (Gbassi and Vandamme, 2012). Gelatin is amphoteric in nature, due to the 
presence of carboxylic and aminoguanidine groups (Saravanan and Rao, 2010), and for this, it shows 
the ability to have synergistic effects with anionic gel-forming polysaccharides such as gellan gum 
(Krasaekoopt et al., 2003) or alginate (Annan et al., 2008). The two mentioned polymers are miscible 
at pH > 6 because they both carry net negative charges. However, the net charge of gelatin becomes 
Figure 1.7 - Schematic drawing and calcium coordination of the egg-box model: two consecutive guluronate 
chains in calcium alginate junction zones. Dark circles represent the oxygen atoms involved in the 
coordination of the calcium ion (Sikorski et al., 2007). 
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positive when the pH is adjusted below its isoelectric point and causes a strong interaction with the 
negatively charged gellan gum and alginate (Huq et al., 2013; Mortazavian et al., 2007). 
 
 
According to Annan et al. (2008), encapsulation in alginate-coated gelatin microspheres significantly 
(P < 0.05) improved the survival of probiotic bacteria (Bifidobacterium adolescentis) in the harsh 
acidic conditions of simulated gastric juice in comparison to free cells.  
Gelatin is easily solubilized in most polar solvents due to the presence of charged amino acids, 
forming colloidal solutions. This means that gelatin by definition is a hydrocolloid (Armisen and 
Galatas, 2009).  
 
 
SOL state GEL state 
Figure 1.9 - Mechanism of gelatin gelation. A gelatin solution forms a gel upon cooling due to the formation 
of triple helices stabilized by intermolecular hydrogen bonds, while gel heating leads to the reverse process 
(Eysturskarð, 2010). 
Figure 1.8 - Gelatin repeating structure responsible for triple helix structure (Duconseille et al., 2015). 
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Due to the above-mentioned properties, the food industry is one of the major consumers of gelatins. 
For example, jellies, represent food products that take advantage of the thermoreversible gel 
formation and the “melt-in-the-mouth” texture of gelatin. In addition, other important nutritional and 
health properties are: high-quality source of protein, free of cholesterol and sugar, and safe (GRAS 
status) (Armisen and Galatas, 2009). Moreover, gelatin is easily digested and utilized by the human 
organism. 
However, recent research has focused on finding a suitable alternative to gelatin microencapsulation 
because it is from animal sources, and this is not accepted by a specific group of consumers based on 
dietary preferences and religious beliefs.  
 
1.6.3 Spray drying 
Spray-drying is one of the oldest processes and the most widely used encapsulation technique in the 
food industry (Nedovic et al., 2011). 
The principle of spray drying is dissolving, emulsifying, or dispersing the active core in an aqueous 
solution of the chosen carrier material. The mixture is subsequently atomized into a hot chamber (Jan 
Zuidam and Shimoni, 2010). This promotes rapid evaporation of the solvent (water). The capsules 
are obtained as a dry powder after separation from the drying air at the outlet at a lower temperature 
(Rokka and Rantamäki, 2010; Timilsena et al., 2020). 
The spray drying technique is flexible, continuous, fast, and relatively economical. It produces 
particles of good quality, which size is less than 40 µm, very stable, thus allowing a significant 
increase in shelf-life, and when adequately performed, is highly reproducible (De Vos et al., 2010; 
Iravani et al., 2015). 
However, this technology also has some disadvantages: the active component may be exposed and 
thus representing problems when considering the technique for encapsulation of probiotics, where 
the bacteria may leak into the product when some hydration occurs (De Vos et al., 2010). Another 
limitation is the high temperature required to facilitate water evaporation that is not compatible with 
the survival of all types of probiotics, reducing their viability in the final product (Rokka and 
Rantamäki, 2010). 
Besides, once the capsules are obtained from other encapsulation techniques, this procedure can 
isolate them as a dry powder for ease of handling and storage. For this purpose, different drying 
procedures have been used, including spray drying, air drying, freeze-drying, and fluid bed drying 
(Cook et al., 2012).  
In spray chilling or spray cooling, the active material to be encapsulated is mixed with the carrier and 
atomized by chilled or cooled air instead of heated air as in spray drying (Gibbs et al., 1999). 
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1.7 Aim of the thesis 
Due to the fastidious nature of many probiotic bacteria, especially S. thermophilus, survival in 
sufficient amounts during passage through the human gastrointestinal tract (GIT) is a key factor to 
confer health benefit to the host. Among the different strategies proposed to protect bacteria cells, 
microencapsulation technique offers a great potentiality in the delivery of viable cells.  
 
The aim of this project was to investigate the most suitable encapsulating agent for 
microencapsulation of the potential probiotic strain S. thermophilus TH982, isolated from a dairy 
environment. Using four types of substances to encapsulate bacteria cells, different parameters have 
been analyzed in order to evaluate the survival of viable cells to the encapsulation procedure, storage 
in skimmed milk, passage through simulated gastrointestinal tract and final released in the lower 
intestinal tract. The materials employed in the extrusion process for the formation of alginate-based 
capsules are represented by three categories: a polysaccharide (inulin), a protein (gelatin) and a 
human milk oligosaccharide (2’-fucosyllactose).
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2 MATERIALS AND METHODS 
2.1 Bacterial strain 
A potential probiotic bacterium strain, S. thermophilus TH982, which has the characteristics of good 
potential EPS produces, great resistance to simulated gastrointestinal conditions, high extracellular 
folate production (Tarrah et al., 2018), was used as the target strain in this work. This strain was 
studied for hemolytic activity from the safety aspect, and it was detected as γ-hemolytic (i.e., without 
hemolytic activity). 
According to Treu et al. (2014), TH982 has been isolated in the Campania region from whey and 
curd, respectively, obtained from mozzarella di bufala campana DOP cheese (pasta filata cheese) 
production. The strain was also characterized for genome sequence by Treu et al. (2014).  
 
2.2 Bacteria and growth conditions  
Pure culture of probiotic bacteria (S. thermophilus TH982) was obtained in freeze-dried form from 
the Department of Agronomy, Food, Natural resources, Animals and Environment, University of 
Padova, Italy.  
Stock culture of S. thermophilus TH982 was stored at -80 °C in M17 broth (Sigma-Aldrich) 
containing glycerol (25% v/v) and was activated by inoculating the culture into 45 ml of M17 (Sigma-
Aldrich) broth medium (42 g of M17 in 1 liter of distilled water) for 24 h at 37 °C. The reactivated 
cells were centrifuged at 5500 rpm for 5 min at room temperature, and subsequently, the supernatant 
was discarded to obtain bacteria pellets. 
The cells were then washed twice by sterile distilled water and used in the encapsulation process. 
Fresh cell suspensions were prepared for each experiment and numerated by micro drop technique 
plating on M17 agar. Plates were incubated for 48 h at 37 °C.  
 
2.3 Microencapsulation procedure 
The agents used for the microencapsulation of S. thermophilus TH982 are represented by sodium 
alginate (S), a linear heteropolysaccharide of D-mannuronic and L-guluronic acid extracted from 
various species of algae, used as main encapsulating material (control) (Cook et al., 2012); gelatin 
(G) from porcine skin, a mixture of heterogenous polypeptides which has the ability to form 
thermoreversible gels (Burey et al., 2008); inulin (I), a linear polydisperse mixture of β-2-1 linked D-
fructose molecules and a prebiotic, which resist hydrolysis by human small intestinal digestive 
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enzymes (Roberfroid, 2005); 2’-fucosyllactose (F), a human milk oligosaccharide, and a bioactive 
molecule which protect the breastfed infant from pathogen acting as a prebiotic (Kunz et al., 2000; 
Newburg et al., 2005).  
The extrusion technique was carried out in a modified version described earlier by Mirzaei et al. 
(2012) and Liao et al. (2019). 
All glassware and solutions used in the protocols were sterilized at 121 °C for 15 min. 
The microencapsulating matrix of probiotic cells was prepared through the combination of 2% (w/v) 
sodium alginate with 2% (w/v) inulin, 2% (w/v) gelatin, 2% (w/v) 2’-FL, and sodium alginate alone 
used as control. For each capsule type, the different matrices were mixed, adjusted to the final 
concentration of 2%, and added to the TH982 pellet suspension. 
The mixture was injected through a sterile syringe with a needle size of 450 µm of diameter into 
sterilized 0.3 M CaCl2 hardener solution. The droplets formed gel spheres immediately. The distance 
between the bottom of the nozzle and the surface of the CaCl2 solution was 10 cm (Figure 2.1). 
After 30 min in the hardening solution (CaCl2), the obtained capsules were collected by filtration and 














2.4 Morphology of capsules 
The morphology of the microcapsules was examined using an optical stereo microscope (Olympus, 
Tokyo, Japan).  
 
2.5 Encapsulation efficiency 
To break the encapsulated polymers, 1 g of capsules was suspended in 9 ml of 10% (w/v) sterilized 
sodium citrate and homogenized for 1-2 min. To determine the viable concentration in capsule 
Figure 2.1 - Microencapsulation of bacteria cells with different concentration of encapsulating matrices using 
extrusion technique.  
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solutions, before encapsulation, 1 ml of each type of capsule matrix was added to 9 ml of distilled 
water. 
The homogenized samples were serially diluted with sterile distilled water, and the viable cells were 
determined and expressed as log colony-forming units per gram (log CFU/g) for capsules, and log 
colony-forming units per milliliter (log CFU/ml) for matrices, by plating 20 µl of the appropriate 
diluted bacterial cultures, with micro drop technique, on M17 agar plates and incubation at 37 °C for 
48 h.  
The encapsulation yield, or encapsulation efficiency (EE), was determined using the given equation 
(Chávarri et al., 2010):  
EE %= (N1/N0) x 100 
 
Where N1 is the number of viable entrapped TH982 cells (log CFU/g) released after the encapsulation 
procedure, and N0 is the number of viable cells (log CFU/ml) added into the mixture before 
encapsulation.  
To perform the micro drop technique, 100 µl of each solution was added to 900 µl of sterile water, 
and serial decimal dilutions of the solution were performed down to 10-9. Then, 20 µl aliquots of each 
dilution were spotted on the surface of M17 agar plates. The experiment was executed using three 
technical replicates. 
 
2.6 Storage in skimmed milk 
To determine the survival of encapsulated TH982 during the storage, 1 g of microcapsules was 
suspended in 9 ml of 10% (w/v) reconstituted skimmed milk as it is used for the preparation of most 
of the fermented dairy products (Singh et al., 2019), and stored under refrigerated conditions (4 °C) 
for different time intervals (0, 7d, 14d, 21d). 
The survival of free (non-encapsulated) bacteria cells was determined by adding 9 ml of 10% (w/v) 
reconstituted skimmed milk to 1 ml of free cells as well. 
At each time interval, 1 g of capsules was collected, centrifuged at 5500 rpm for 5 min, and the 
supernatant was discarded. The cells were then released in 10% (w/v) sodium citrate, serially diluted, 
and plated on M17 agar.  
The survival was determined as the number of cells (log CFU/g) recovered during different storage 




2.7 Survival under simulated gastrointestinal conditions 
The survival of free cells and encapsulated cells was evaluated under in vitro simulated 
gastrointestinal conditions.  
The simulated gastrointestinal conditions were obtained using a basic juice, gastric juice, and 
intestinal juice. The basic juice was prepared by dissolving (per liter): 1.12 g potassium chloride, 2.0 
g sodium chloride, 0.11 g calcium chloride, and 0.4 g potassium dihydrogen phosphate in distilled 
water. The basic juice was sterilized by autoclaving at 121 °C for 15 min.  
The simulated gastric juice (SGJ) and simulated intestinal juice (SIJ) were prepared using a modified 
method from Singh et al. (2019). 
The gastric juice consisted of 0.01 g/l of swine pepsin (Sigma-Aldrich) and 0.01 g/l of swine mucin 
(Sigma-Aldrich) added directly to the sterile basic juice. The pH was adjusted to 2.5 with 1 N HCl, 
and the liquid was filter-sterilized using a 0.22 µm membrane filter (Sigma-Aldrich). 
The intestinal juice contained (per liter of basic juice): 0.01 g pancreatin (Sigma-Aldrich), 0.08 g Ox-
bile extract (Sigma-Aldrich) and 0.01 g lysozyme (Sigma-Aldrich). The pH was adjusted to 7.5 with 
1 N NaOH, and the juice was filter-sterilized. Both gastric and intestinal juices were prepared fresh 
on the day of the experiment. 
Overnight bacteria cells were obtained after two-times subculturing in M17 broth, and the capsules 
were prepared fresh as described above. One g of capsules was added to 9 ml of SGJ and incubated 
at 37 °C for 1 h to evaluate the survivability of TH982 using different encapsulation matrices. The 
experiment was performed for all different capsule types and the bacteria alone.  
After the incubation period, the cells’ viability was evaluated using the technique mentioned earlier 
in the storage section.  
For the survival of TH982 under gastrointestinal conditions, 9 ml of SIJ was added following gastric 
juice incubation. Capsules and free cells with simulated gastric and intestinal juice were left at 37 °C 
for a further 2 h. After the incubation period, the cells’ viability was evaluated using the technique 
mentioned earlier in the storage section. The experiment was performed using three technical 
replicates. 
 
2.8 Release kinetics 
The release kinetic study was carried out in intestinal fluid without enzymes. 
The release of encapsulated S. thermophilus TH982 was evaluated according to Yongsheng et al. 
(2008), Wang et al. (2016) and Shi et al. (2013a) with some modifications.  
 62 
A simulated intestinal fluid was prepared according to Shi et al. (2013a) (6.8 g/l of K2HPO4, 50 mM) 
and stirred until complete dissolution by using a magnetic stirrer. The pH was adjusted to 7.5 with 1 
N HCl and subsequently sterilized by autoclaving at 121 °C for 15 min.  
Microcapsules (1 g) from different matrices were added to 9 ml of SIJ pH 7.5 (without enzymes), and 
incubated at 37 °C using a 100 rpm rotator. At predetermined time intervals (initial, after 30, 60, 90, 
120, 150, 180 min), 100 µl of solutions were taken from each capsule type, serially diluted, and plated 
using the micro drop technique on M17 agar to detect the number of released cells. The number of 
released cells was determined after 48 h of incubation at 37 °C and expressed as log CFU/ml of 
K2HPO4 solution.  
 
2.9 Statistical analysis  
Data were analyzed using one-way analysis of variance (ANOVA). Tukey’s test was used as post hoc 
analysis by the GraphPad Prism software (version 7, GraphPad Software, Inc., San Diego, CA, United 
States). In general, results were considered significantly different when P values were lower than 
0.05.  
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3 RESULTS AND DISCUSSION 
3.1 Encapsulation efficiency 
The encapsulation efficiency (EE) of the four microcapsule types is shown in Table 3.1.  
The EE is a combined parameter that describes the survival of viable cells and the efficacy of 
entrapment during the encapsulation procedure (Heidebach et al., 2012). The efficiency of entrapping 
cells in capsules was different among two groups of encapsulating matrices, as reported in in Table 
3.1.  
The yield of TH982 cells co-encapsulated with the oligosaccharide 2’-FL (96.13%) was significantly 
higher (P < 0.01) than that of cells encapsulated with sodium alginate alone (91.07%), used as control.  
Furthermore, the yield of encapsulation with sodium alginate and inulin (98.61%) was similar (not 
statistically different) to that of 2’-FL. 
The high EE derived from the combination of sodium alginate with oligosaccharide (2’-FL) and 
polysaccharide (inulin) might be due to the decrease in the porosity of the gel-beads and thus 
reduction in the leakage of entrapped TH982 cells (Liao et al., 2019). Besides, incorporating 
prebiotics as materials for encapsulation may better protect probiotics in food systems and the 
gastrointestinal tract (Sathyabama et al., 2014). 
By contrast, the number of viable cells encapsulated in sodium alginate alone and in combination 
with gelatin indicated no significant difference, with EE 91.07% and 90.50%, respectively.  
 
 Table 3.1 - Encapsulation efficiency of S. thermophilus TH982 using different encapsulating matrix. 
Superscripts letters indicate statistically significant (P  0.05) differences between different type of encapsulating 
matrix. 
Values are the mean ± standard deviation (SD) of triplicate experiments (n=3).  
S: sodium alginate; S+I: sodium alginate + inulin; S+G: sodium alginate + gelatin; S+F: sodium alginate + 2’-FL.  
 
 
The main reason for an EE below 100% is linked to cell damage due to detrimental conditions caused 
by the encapsulation process itself, such as shear stress and use of concentrated solutes. Furthermore, 
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during time (30 min) required for hardening of capsules, a physical loss of cells can occur in 
significant numbers (Heidebach et al., 2012). 
It should also be noted that a dissolution process is required to determine the number of viable cells 
in the microcapsules, and hence an incomplete disintegration can underestimate the EE value found.  
In particular, for the solubilization of alginate-based capsules, sodium citrate (10% w/v) was used, 
which is a chelating agent (such as phosphate and lactate) (Liao et al., 2019). It can chelate calcium 
from the egg box structure, leading to destabilization of alginate coating and effective release of cells 
(Annan et al., 2008).  
 
3.2 Morphology of capsules 
During the extrusion of the sodium alginate-based matrix into the CaCl2 bath, wet spherical capsules 
were immediately formed by establishing cross-linkage between carboxyl groups and Ca2+ ions 
(Vaziri et al., 2018). 
The images of the microcapsules entrapping the S. thermophilus TH982 indicate that all capsules 
were globular and irregular in shape with a rough surface and display a drop-like shape with a small 
tail (Figure 3.1). This result is probably due to the high surface tension of the hardening solution used 
(CaCl2) that results in the imperfect sphere formation (El-shafei et al., 2018). However, no surface 
cavities or fractures were detected.  
The capsules with sodium alginate and gelatin (B in Figure 3.1) showed a more dense structure, as 
confirmation of gelatin solution viscosity, due to electrostatic interactions between the amino groups 
of gelatin and carboxyl groups of alginate which enabled cells to resist to enzymatic and acidic 
hydrolysis (Vaziri et al., 2018).  
The size range obtained might not be suitable for specific dairy product applications, and in the future, 
the evaluation of sensory characteristics of these capsules would be of interest. 
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3.3 Storage in skimmed milk 
Results in Figure 3.2 illustrate that the viability of all the encapsulated S. thermophilus cells during 
storage in skimmed milk at 4 °C for 21 days showed little viable cell reduction from the initial count, 
which was around 109 CFU/g.  
At the end of the storage period, the cell reduction was recorded as 1.79, 1.97, 0.46 and 1.62 log 
CFU/g decrease for S. thermophilus TH982 cells encapsulated with S, S+I, S+G, S+F, respectively.  
From the data shown in Figure 3.2, the free cells (TH982) showed the highest viability during the 
storage period. In this regard, after 21 days, the analysis of viable cells of free TH982 revealed no 
significative differences between initial and final numbers (8.90 ± 0.08 log CFU/ml at initial time 
and 8.94 ± 0.05 log CFU/ml after 21 days). Also, gelatin as a co-encapsulating agent indicated that 
after 21 days the survival of cells was comparable to that of non-encapsulated ones and statistically 
different (P < 0,0001) to the control (sodium alginate alone), achieving a final number of viable 
bacteria of 8.04 ± 0.09 log CFU/g (initial number 8.50 ± 0.04 log CFU/g of capsules). 
Notwithstanding, the other types of encapsulating matrices displayed a decrease in the number of 
viable cells after 21 days. Capsules of sodium alginate alone and in combination with the two 
prebiotics (inulin and 2’-FL) revealed a similar drop in viable bacteria counts; in particular a final 
count of 6.82 ± 0.19 log CFU/g of sodium alginate capsules (initial number of 8.61 ± 0.19 log CFU/g), 
Figure 3.1 - Pictures taken by amplification of the samples with a stereo microscope; magnification 100X.  
A: sodium alginate (S); B: sodium alginate + gelatin (S+G); C: sodium alginate + inulin (S+I); D: sodium alginate 
+ 2’-FL (S+F).  
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7.07 ± 0.20 log CFU/g of sodium alginate with inulin capsules (initial number of 9.04 ± 0.12 log 
CFU/g) and 7.35 ± 0.02 log CFU/g of sodium alginate with 2’-FL capsules (initial number of 8.97 ± 
0.07 log CFU/g) were detected. 
This result is in contrast with the majority of the studies performed to evaluate the survival of 
encapsulated bacteria under refrigerated conditions. For instance, encapsulation improved the 
stability of L. plantarum during storage (Wang et al., 2016), and encapsulation of bacteria in alginate 
was found to improve survival rates by one log when compared to free cell counts when stored in 




Since FAO and International Dairy Federation (IDF) have recommended that the least viability of 
probiotics should be 107 CFU/g of product at the time of consumption (Shiby and Mishra, 2013), the 
four encapsulating materials that were used in this study were efficient in maintaining the required 
viability of S. thermophilus after refrigerated storage in skimmed milk. The high numbers suggested 
by IDF have been proposed to compensate for the possible reduction in the numbers of the probiotic 
organisms during passage through the stomach and the intestine. 
It is important that the cells remain viable throughout the projected shelf-life of a product so that 























TH982 Sodium alginate Sodium alginate+inulin
Sodium alginate+gelatin Sodium alginate+fucosyllactose
Figure 3.2 - Survivability of S. thermophilus TH982 encapsulated and free cells during 21 days storage in 
skimmed milk 
Values shown are means ± standard deviations (n = 3) 
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The viability of probiotic bacteria in food products is affected by many intrinsic and extrinsic aspects 
such as dissolved oxygen and oxygen permeation through the package, post acidification in fermented 
products (lactic and acetic acids), pH, storage and incubation temperature, duration of fermentation, 
production of hydrogen peroxide due to bacterial metabolism, and processing conditions (Capela et 
al., 2006; Shah, 2000). Moreover, the specific strains used, the interaction between species (proto-
cooperation), availability of nutrients, and the presence of growth promoters and inhibitors, can affect 
the survivability of viable cells.  
The great survivability of free cells in skimmed milk is probably due to the fact that S. thermophilus 
is highly adapted to grow on lactose as energy source, which is transported by lactose permease 
(LacS) and, once entered the cell, is hydrolyzed into glucose and galactose by β-galactosidase (LacZ) 
(Hols et al., 2005). Hence, the entrapment of TH982 into capsules of different matrices has probably 
led to reduction of diffusion of lactose through the capsule layer or membrane limiting the possibility 
to use a carbon source.  
Considering that viability is affected by cell concentration (Shah, 2000), it can be hypothesized that 
bacterial cells entrapped in a capsule represent a microenvironment with a high cell concentration.  
The addition of glucose oxidase in yogurt processing has been reported as a potential technological 
solution to reduce the dissolved oxygen, thus minimizing the oxidative stress and positively affect 
probiotics growth, which have anaerobic characteristics (Batista et al., 2015). Therefore, to positively 
affect probiotics growth during storage, which can subsequently increase the number of bacteria to 
reach the gut, one possible solution can be represented by the addition of glucose oxidase to food 
products (Batista et al., 2015), thus inclusion of these enzymes in the encapsulating matrix could be 
considered. 
 
3.4 Survival under simulated gastrointestinal conditions 
Probiotic microorganisms must be resistant to gastric juices and be able to grow in the presence of 
bile salts or must be inserted in a food vehicle that allows them to survive passage through the stomach 
and exposure to bile (FAO/WHO, 2006). 
The survival of probiotics in the gastrointestinal environment is a major limitation for their 
effectiveness, and microencapsulation represents a method to provide significant protection. The 
survival of free and encapsulated probiotic S. thermophilus TH982 during 1, 2, and 3 h of incubation 
in simulated gastrointestinal conditions is presented in Figure 3.3.  
After 1 h of gastric juice, the highest reduction of viable cells was found, as aspected, for free TH982, 
as the initial number of 10.40 ± 0.10 log CFU/ml was diminished by 0.95 log CFU/ml. A notable 
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decrease in viability after 3 h of gastrointestinal conditions was confirmed for free TH982 cells, that 
diminished by approximately 1.60 log CFU/ml, dropping to 8.79 ± 0.02 log CFU/ml. 
By contrast, for encapsulated cells with alginate alone, only 1.05 log CFU/g reduction of viable cells 
was observed, implying that microencapsulation provided effective protection compared to the free 
cells, as reported by Liao et al. (2019). This protection offered by sodium alginate might be related 
to the establishment of a hydrogel barrier through an external layer of sodium alginate that retarded 
the permeation of juices into the capsules and thus interaction with the probiotic cells (Jiménez-
Pranteda et al., 2012). From a structural perspective, it might be explained by the acid-induced water 
loss of alginate in low pH. When pH is below the pKa values of carboxyl functions, alginate gets 
converted into alginic acid gel structures by H-bonds with the release of calcium ions resulting in a 
more dense gel due to water loss (Doumèche et al., 2004).  
According to Sun and Griffiths (2000) the low pH conditions of the stomach (less than 2) resulted in 
dramatic decrease in the viability of Bifidobacterium strains. However, after microencapsulation of 
cells, the death rate was around 0.67% under the same conditions. When placed into simulated gastric 
fluid, free cells were exposed to the low pH immediately, while capsules might provide protection: 
the bacteria cells in the core and the surface of the capsules were subjected to a different pH. This pH 
gradient in capsules was dependent on the bead size and the exposure time in simulated gastric juice 
(Sun and Griffiths, 2000). 
Capsules consisting of sodium alginate and gelatin showed low survivability during gastric 
environment; indeed the reduction of viable cells was higher (0.52 log CFU/g decrease) than the loss 
of encapsulated cells with inulin (no reduction detected) after 1 h of gastric condition (pH 2.5). This 
fact might be due to a variation of pH, which changes the gelatin charge with the amino and carboxyl 
groups, so the modification of cross-links and the structure of the chains could influence the swelling 
behavior of gelatin capsules (Duconseille et al., 2015).  
An important result was given by the two types of prebiotics used as a co-encapsulating agent with 
sodium alginate: inulin and 2’-FL. After 1h of exposure to gastric conditions, only inulin indicated 
significant protection compared to the other agents (no reduction detected). However, after 
gastrointestinal incubation, 2’-FL and inulin revealed the highest cell survivability, leading to a very 
low, not significant, cell reduction (less than 0.45 log CFU/g decrease for both agents).  
The decrease in the viability of free bacteria during gastric environment transit (0.95 log CFU/ml 
decrease) was also higher than that observed during 3h gastrointestinal (0.69 log CFU/ml decrease) 
incubation. In contrast, encapsulated bacteria experienced a greater reduction during gastrointestinal 
transit rather than in gastric conditions alone. This behavior may be due to the fact that alginate is 
stable in low-pH solutions: the ionotropic alginate gel formed by Ca2+ cross-linking of carboxylate 
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groups is insoluble at low pH, but exposure to neutral or alkaline pH solubilize the alginate, causing 
swelling (Gandomi et al., 2016). 
As soon as the probiotic cells encapsulated leave the stomach (pH 2.5), the low pH around the beads 
is neutralized by the intestinal juice (pH 7.5), and as a consequence, the capsules are softened at 
higher pH and might be broken by the peristalsis of the small intestine, causing the released of bacteria 
cells from the capsules (Sun and Griffiths, 2000).  
Regarding the gastric fluid pH, it should be noted that in the literature the values vary between 1 and 
3. This pH range covers the values generally observed in the human stomach. Specifically, pepsin is 
often used as a gastric enzyme model, and generally, the average time to empty half of the stomach 
contents is 90 min (Sun and Griffiths, 2000). The intestinal pH values used in different studies are 
between 6.5 and 8. These values reflect the pH usually met in the gut (Gbassi and Vandamme, 2012).  
Concerning the exposure time, it has to be noted that the gastric transit rate of both liquids and solids 
is significantly slower in women than in men, while ageing accelerates the small intestinal transit 
significantly in both gender. Therefore, gender and age differences have to be considered when 












































Time 0 After 1h gastric After 2h gastrointestinal After 3h gastrointestinal
Figure 3.3 - Survivability of S. thermophilus TH982 encapsulated and free cells during exposure to in vitro 
simulated gastrointestinal conditions. 
Superscript letters indicate statistically significant (P  0.05) differences between different type of encapsulating 
matrix. 
Values shown are means + standard deviations (n = 3) 
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The results of this investigation are in agreement with other studies. As Sultana et al. (2000) reported, 
the co-encapsulation with alginate and prebiotic (resistant starch) demonstrated synergic interaction 
in gelling and, as a result, may help to provide additional protection to the entrapped bacterial cells. 
Another study indicates that encapsulation of probiotic L. rhamnosus in chitosan-coated alginate bead 
exhibited a higher survival rate during gastrointestinal treatments compared to free bacteria, and 
inulin demonstrated a fortification effect, improving the viability of encapsulated bacteria during 
product storage as well as during GIT transit (Gandomi et al., 2016). 
The combination of calcium alginate with prebiotics such as inulin improves the viability of 
probiotics and facilitates the formation of integrated structure of capsules. Researchers found better 
protection of cells in coated capsules after simulated gastric juice of L. casei and B. bifidum, deducing 
that it might be attributed to the addition of inulin, which acts as a prebiotic (Khosravi Zanjani et al., 
2014). 
Sathyabama et al. (2014) tested bacterial growth on different potential prebiotics (sugar beet, chicory, 
and oats) to select the co-encapsulating agent to be used with alginate. The variation in the 
oligosaccharide composition of prebiotic sources might be the reason for the difference in the growth 
rate. The rate at which oligosaccharides are fermented depends on the degree of polymerization, 
glycosidic linkage, degree of branching, and synergy between bacteria during fermentation. They 
found a significant difference among the prebiotics tested on bacterial growth: sugar beet and chicory 
were found to be an efficient prebiotic with high fermentation rate and potent in co-encapsulation 
with probiotics in alginate matrix.  
Prebiotics, such as 2’-FL and inulin, which could provide good protection and even promote cell 
proliferation, appeared to contribute to the growth of S. thermophilus TH982. In addition, 
oligosaccharides are difficult to be decomposed by enzymes in digestive juice but can be metabolized 
by beneficial bacteria in the colon (Liao et al., 2019). It has been further demonstrated that 
oligosaccharides contained in human milk have an extraordinary resistance to hydrolysis by digestive 
enzymes of the small intestine (Engfer et al., 2000). 
Therefore, besides the protective function, oligosaccharides entrapped in the capsule could also 
provide selective carbon sources for probiotics and even promote the proliferation of some strains.  
A choice of a microencapsulation system has to consider the best suitable technology to preserve and 
even promote the functionality of probiotics. One “gentle” approach for encapsulation is the extrusion 
technique in combination with matrix molecules (Nedovic et al., 2011). Alginate is the most widely 
used encapsulating material, thanks to its low cost, ease of handling, and biocompatibility 
(Krasaekoopt et al., 2004). According to Jiménez-Pranteda et al. (2012), L. plantarum encapsulated 
with jamilan:gellan gum (1%:1%) after 2 h of simulated gastrointestinal juice showed a lack of 
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protection, while L. rhamnosus demonstrated a minor decrease. This behavior demonstrated that the 
biocompatibility of certain encapsulating polymers with specific bacteria is of great importance and 
may even differ among strains of the same probiotic species (Rodrigues et al., 2011).  
Annan et al. (2008) noted that the simulation of gastric juices for in vitro studies tends to overestimate 
viability losses that would occur in vivo: during and after a meal, the buffering capacity of foods may 
temporarily elevate the gastric pH so that the cells can reach their site of action in sufficiently high 
numbers to produce a physiological effect (Mainville et al., 2005). As a confirmation, non-protected 
cells consumed in a dried form have lower recovery levels in stools than those consumed in milk or 
cheese (Champagne and Fustier, 2007). 
From this study, it is possible to conclude that the most advantageous encapsulating agents for the 
transit in the gastrointestinal tract are prebiotics: inulin and 2’-FL (0.28 log CFU/g and 0.44 log 
CFU/g decrease respectively from the initial number of viable cells).  
Furthermore, considering the storage period, using these two types of matrices, the reduction that 
occurs after 21 days at 4 °C in skimmed milk was 1.97 log CFU/g for inulin and 1.62 log CFU/g for 
2’-FL (not statistically different). It can be concluded that, if the number of cells in the food product 
is equal or higher to that required at consumption time (107 CFU/g), the sodium alginate-based 
microencapsulation with 2% of inulin or 2% of 2’-FL might maintain a required number of viable 
cells after the gastrointestinal passage. 
 
3.5 Release kinetics 
To evaluate the survival under gastrointestinal conditions, it is essential to ensure that the capsules 
give protection through the simulated gastrointestinal passage, and ensure that the encapsulation 
matrix allows a release of viable and metabolically active cells in the intestine (Gbassi and 
Vandamme, 2012). The use of capsules minimizes the bactericidal effects of the stomach 
environment and maximizes the number of probiotic cells reaching the ileum. 
After passing through the stomach, microcapsules will reach the intestine with higher pH and release 
the probiotic cells (Shi et al., 2013b). The release of cells from microcapsules in the colon is essential 
for the growth and colonization of probiotics. In the absence of this event, the organisms in the beads 
will be washed out from the body without exerting any beneficial effect (Sabikhi et al., 2010). The 
release can be time-, site-, rate-, stimulus-specific or triggered by changes in pH, temperature, 
irradiation, or osmotic shock. The steps involved in the release of an active agent (bacteria cells) that 
is dissolved in the matrix are (Pothakamury and Barbosa-Cánovas, 1995): A) diffusion of the active 
agent to the surface of the matrix; B) partition of the active agent between the matrix and the elution 
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medium (i.e., the surrounding food or intestinal environment); C) transport away from the matrix 
surface. 
The release of encapsulated S. thermophilus TH982 after incubation in simulated intestinal fluid (pH 
7.5) was evaluated at 30, 60, 90, 120, 150, and 180 min, as reported in Figure 3.4. The release 
characteristics have been evaluated at a predetermined time point, every 30 min up to 180 min in a 
simulated intestinal fluid as reported by Shi et al. (2013a). 
Just after 30 min of agitation (100 rpm) at 37 °C in K2HPO4, a quick release of cells from sodium 
alginate based encapsulation with the prebiotic 2’-FL was detected. Similarly, cells encapsulated and 
co-encapsulated with different types of oligosaccharides started to be slowly released after 30 min 
into the simulated intestinal fluid (pH 7.4) (Liao et al., 2019), reaching a plateau (Figure 3.4). 
Considering the initial number of cells entrapped in this type of capsules (9.73 ± 0.04 log CFU/g of 
capsule), the count of cells released in the simulated intestinal fluid after 30 min was 8.83 ± 0.04 log 
CFU/ml, representing the highest value even in comparison with the release of other types of 
encapsulating matrices after 180 min. This result is a confirmation of what was observed while 
performing the experiment: after 30 min, there was a visible dissolution and solubilization of 2’-FL 
capsules, behavior not found in other capsules. Moreover, the survival of released cells suggests that 
once liberated, S. thermophilus TH982 is able to withstand the simulated intestinal conditions at pH 
7.5; as evidence, after 180 min, the count of cells released from capsules with 2’-FL was 9.72 ± 0.05 
log CFU/ml, which means 99.89% of initial entrapped cells, representing a result not reported in other 
studies in the literature up to date. An efficient release of viable and metabolically active cells in the 
intestine is one of the microencapsulation aims (Mandal et al., 2006). 
While the release profile indicated that alginate-based encapsulation with 2’-FL had fast release 
property in intestinal fluid, the ability of sodium alginate (initial count 9.43 ± 0.04 log CFU/g), 
sodium alginate with gelatin (initial number 9.62 ± 0.03 log CFU/g), and sodium alginate with inulin 
(initial count 9.68 ± 0.03 log CFU/g) to release the entrapped cells is lower.  
After 30 and 90 min, the relase profile was similar in capsules with sodium alginate alone (6.54 ± 
0.04 log CFU/ml released after 30 min and 7.07 ± 0.11 log CFU/ml released after 90 min) and in 
combination with gelatin (6.52 ± 0.06 log CFU/ml released after 30 min and 6.91 ± 0.19 log CFU/ml 
released after 90 min). However, after 180 min of exposure, co-encapsulation with the fructan 
polysaccharide (inulin) (initial count 9.68 ± 0.03 log CFU/g of capsules) and protein (gelatin) (initial 
count 9.62 ± 0.03 log CFU/g of capsules) demonstrated a comparable release, 7.35 ± 0.14 log CFU/ml 
and 7.15 ± 0.10 log CFU/ml, respectively. This result is quite unexpected because during simulation 
of passage in the gastrointestinal tract, inulin showed a behavior similar to 2’-FL. Thus, there was a 
significant difference between the release kinetic of the two prebiotics, inulin and 2’-FL (P < 0.0001), 
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at the end of incubation time, showing a difference of 2.37 log CFU/ml in the number of released 
cells.  
The ability to release the cells from capsules of sodium alginate and gelatin was the lowest detected 
(7.15 ± 0.10 log CFU/ml). This result is in accordance with Li et al. (2009) which reported that the 
incorporation of gelatin as a co-encapsulating agent with alginate did not affect the kinetics of release 
from capsules.  
The second highest release of entrapped cells was observed in capsules of sodium alginate alone, 
specifically 7.45 ± 0.10 log CFU/ml released at the end of the incubation (180 min), while inulin 
showed a low capacity of releasing probiotic cells in the small intestine. 
 
 
The release of the cells from microcapsules in the colon is essential for the growth and colonization 
of probiotics (Chen et al., 2014). When the capsules are opened in the small intestine, the released 
cells are expected to arrive in the large intestine (Mortazavian et al., 2007). Iyer et al. (2004), 
investigated the survival and the subsequent release of alginate capsules in samples of different 
sections of the gastrointestinal tract (stomach, duodenum, anterior small intestine, posterior small 
intestine, and colon). It was demonstrated that the principal site of bacterial release in the gut was the 
small intestine (pH 6.5-6.8); thus, the majority of cells were released in both anterior and posterior 
ileal contents in 1 h. This represents a significant result because many important functions attributed 




























Sodium alginate Sodium alginate+inulin Sodium alginate+gelatin Sodium alginate+fucosyllactose
Figure 3.4 - Release of entrapped cells of S. thermophilus TH982 in simulated intestinal environment. 
Values shown are means ± standard deviations (n = 3) 
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segment of the gut is important for the presence of Peyer’s patches and other gut-associated lymphoid 
structures (GALTs) that are thought to play a critical role in immunomodulation (Iyer et al., 2004). 
Many studies investigated the release of encapsulated probiotics in simulated intestinal juice. Similar 
to our observations, Sabikhi et al. (2010) reported the release of encapsulated L. acidophilus in 
alginate-starch microspheres using simulated colonic juice with the same formulation (KH2PO4, pH 
7.4 ± 0.2 during 2.5 h). They found that cells count after 150 min of incubation was 7.45 log CFU/ml, 
suggesting that all the microencapsulated cells were released at this time (initial number of 7.47 log 
CFU/g of capsule). Although 150 min is approx the same time needed for intestinal transit of 
microflora, they did not found a significant release after 30 or 60 min.  
Another study pointed out a progressive release of viable cells from whey-protein-based 
microcapsules in simulated intestinal conditions. The researchers attributed the considerable increase 
of 3.5 log in cell number after 1 h of exposure to simulated pancreatic juice not only to cell 
multiplication, but also to a massive release of uninjured bifidobacteria from degraded microcapsules 
and/or recovery of sublethally injured cells (Picot and Lacroix, 2004). 
In a different study, L. casei was encapsulated in different alginate concentrations (2%, 3%, or 4%), 
and different parameters were evaluated. The survival of entrapped cells in low pH and high bile salt 
concentration increased proportionately with increasing alginate concentrations. However, the release 
of bacteria from capsules in simulated colonic pH solution (KH2PO4, pH 7.4 ± 0.2) was not affected 
by different alginate concentrations after 60 min of exposure (Mandal et al., 2006). On the other hand, 
a significantly decrease of the release rate of encapsulated probiotic bacteria from microspheres was 
detected with the increase of alginate concentrations in alginate-milk microspheres (Shi et al., 2013a). 
An important aspect when performing microencapsulation of probiotics to improve survival in the 
gastrointestinal tract is the definition of the physicochemical characteristics of the encapsulating 
materials in order to predict their mechanisms of disintegration or dissolution under varying 
conditions of pH and salinity and their interactions with probiotic cells or other components present 
in the digestive tract (Gbassi and Vandamme, 2012). As an example, Chen et al. (2014) found that 
the dissociation of alginate-based gel network is due to electrostatic repulsion between whey proteins, 
which are negatively charged, and the carboxyl group from the alginate molecules. Moreover, it is 
well known that alginate gel formed through calcium ions is very rigid and only swells slowly at 
neutral or basic pH, allowing subsequent release in the basic environment of intestinal fluids 
(Sathyabama et al., 2014). 
A fully release of L. plantarum encapsulated with sodium alginate and sodium alginate with inulin in 
60 min of exposure into simulated intestinal fluid has been reported. From the results, it was 
concluded that the release mechanism was probably due to the replacement of calcium ion in the 
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encapsulation matrices. Also, capsules with inulin showed a faster release rate during the first 20 min 
which could have been induced by the addition of inulin in sodium alginate affecting the binding of 
calcium ion (Wang et al., 2016). 
The above-mentioned study indicated a mechanism that may be applied to explain the fast and fully 
released of TH982 ecapsulated with sodium alginate and 2’-FL. This small soluble milk glycan used 
as encapsulating agent in this experiment is formed by fucose linked to the 2 position of β-Gal 
residues of lactose. 2’-FL is considered a neutral HMO (Engfer et al., 2000), hence no electrostatic 
repulsions may occur with the negatively charged carboxyl groups of sodium alginate structure. 
Therefore, the complete release of the cells is probably due to the vigorous interaction of the prebiotic 
structure with the divalent cations (Ca2+) of the sodium alginate network, resulting in a disintegration 
of the “egg box structure”, as observed after 30 min of incubation in K2HPO4. This process is well 
known and recognized to explain the inulin capsules releasing behavior in simulated intestinal fluid, 
a prebiotic commonly used as encapsulating material. However, this represents the first evidence of 
the higher ability of capsules created with a novel molecule (2’-FL), to release active cells in the 




The present study compared the ability of three different alginate-based microcapsules to increase the 
survival of the potential probiotic strain S. thermophilus TH982 in a simulated gastrointestinal 
environment.  
The capsules were successfully obtained by the extrusion technique, as demonstrated from the high 
capacity of entrapment, from 90.50% to 98.61%, found in all the different materials used.  
The outcomes obtained after 21 days of storage of the capsules in skimmed milk indicated that 
microencapsulation might not be a promising method to enhance stability of viable cells at 4 °C, 
except for gelatin. This could suggests that one possible solution to achieve a considerable amount of 
viable cells after storage period, is to consider the addition of bacteria non-encapsulated and 
microencapsulated in the same food product, or to combine gelatin with a molecule, such as 2’-FL, 
which can allow good resistance and released of cells once ingested.  
Interesting findings were obtained after the exposure to a simulated gastrointestinal environment: 
after 3 h of incubation the two prebiotic molecules used (inulin and 2’-FL) revealed a good ability to 
improve protection of TH982, ensuring survival in the harsh acidic conditions and bile concentration, 
as demonstrated by the low reduction of viable cells obtained (0.28 log CFU/g decrease and 0.44 log 
CFU/g decrase, respectively).  
Nevertheless, after further investigation, only the human milk oligosaccharide prebiotic agent (2’-
FL) showed the capacity to release nearly all the TH982 cells encapsulated in simulated intestinal 
juice (pH 7.5). Considering that Human Milk Oligosaccharides are resistant to the low gastric pH and 
enzymatic digestion in the upper gastrointestinal tract, as confirmed in this study, 2’-FL might reach 
the lower gastrointestinal tract intact where it provides nutrients for the colonic microbiota. In view 
of the great release attitude in the intestinal environment, it is possible to conclude that 2’-FL is the 
most suitable encapsulating agent for S. thermophilus TH982 .  
The present work represents the first example of microencapsulation with this novel molecule, 
suggesting that further studied should be of interest to investigate more in details the prebiotic 
properties as encapsulating agent. In particular, different concentrations of 2’-FL and/or co-
encapsulation with other prebiotics should be investigated and compared to optimize the 
encapsulation technology and to obtain the best combination.  
The promising results obtained with this work have been obtained using in vitro tests, hence future 
research should be performed in vivo to assess the mainteinment of this behaviour.  
Finally, considering that capsules containing probiotic cells are designed to be incorporated into foods 
as vehicle (e.g., yogurt), specific morphological studies, including a psychochemical analysis, along 
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